regimen,alternate_name,regimen_type,cancers
5+2d,5 / 2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,5&2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,5 and 2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,5+2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,5/2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,52d,Consolidation after upfront therapy,Acute_myeloid_leukemia
5+2d,5 & 2d,Consolidation after upfront therapy,Acute_myeloid_leukemia
"5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin","5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin",Adjuvant therapy,"Esophageal_cancer,Gastric_cancer,Rectal_cancer"
7+3d & GO,7&3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d+GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d and GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d  and  GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7 and 3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d / GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d/GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7/3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d + GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,73d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,73dGO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7 & 3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7 / 3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & GO,7+3d & GO,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d & Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d/Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d / Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d and Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d  and  Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d+Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Glasdegib,7+3d + Glasdegib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d & Sorafenib,7+3d / Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d  and  Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d & Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d/Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d and Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d+Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d & Sorafenib,7+3d + Sorafenib,"First-line induction therapy, older patients or ""unfit"" patients",Acute_myeloid_leukemia_FLT3-positive
7+3d (high-dose),7+3d (high-dose),"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7 / 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7&3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7/3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7 and 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7+3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),73d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (high-dose),7 & 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7+3d (intermediate-dose),"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7 / 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7&3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7/3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7 and 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7+3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),73d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (intermediate-dose),7 & 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7 / 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7&3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7/3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7 and 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7+3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),73d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7 & 3d,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3d (standard-dose),7+3d (standard-dose),"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7 / 3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7/3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7+3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,73i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7 and 3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7 & 3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i,7&3i,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i+Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i  and  Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i and Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i / Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i + Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i & Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3i & Sorafenib,7+3i/Sorafenib,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7+3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7 & 3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,73m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7 and 3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,MAC,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7&3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7 / 3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
7+3m,7/3m,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
A+AVD,A & AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV  and  AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,AAVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,A and AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV + AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,A+AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV / AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BVAVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV  AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,A / AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV & AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,A/AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV  &  AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,A&AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
A+AVD,BV  /  AVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
ABC,ABC,Metastatic or unresectable disease,Melanoma
ABCP,ABCP,"Advanced or metastatic disease, first-line, nonsquamous",Non-small_cell_lung_cancer
ABV (Vinblastine),ABV,"Kaposi sarcoma, all lines of therapy",Vascular_sarcoma
ABV (Vinblastine),ABV (Vinblastine),"Kaposi sarcoma, all lines of therapy",Vascular_sarcoma
ABV (Vincristine),ABV,"Kaposi sarcoma, all lines of therapy",Vascular_sarcoma
ABV (Vincristine),ABV (Vincristine),"Kaposi sarcoma, all lines of therapy",Vascular_sarcoma
ABVD,ABVD,"Untreated, early-stage favorable (ESF)","Hodgkin_lymphoma_nodular_lymphocyte-predominant,Hodgkin_lymphoma"
"ABVD, DD-DI","ABVD, DD-DI","Untreated, advanced stage",Hodgkin_lymphoma
ABVE-PC,ABVE/PC,"Untreated, pediatric",Hodgkin_lymphoma
ABVE-PC,ABVE-PC,"Untreated, pediatric",Hodgkin_lymphoma
ABVE-PC,ABVEPC,"Untreated, pediatric",Hodgkin_lymphoma
AC,AC,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
AC & Bevacizumab,AC and Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC/Bev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC+Bev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC / Bev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC/Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC+Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,ACBev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC and Bev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC  and  Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC & Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC / Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC + Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC&Bev,Neoadjuvant chemotherapy,Breast_cancer
AC & Bevacizumab,AC & Bev,Neoadjuvant chemotherapy,Breast_cancer
"ACVBP, dose-adjusted","ACVBP, dose-adjusted",All lines of therapy,Post-transplant_lymphoproliferative_disorder
"ACVBP, dose-adjusted",ACVBP,All lines of therapy,Post-transplant_lymphoproliferative_disorder
ACVBP-R,R-ACVBP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ACVBP-R,R/ACVBP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ACVBP-R,ACVBP-R,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ACVBP-R,RACVBP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ACVBP-R,ACVBPR,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ACVBP-R,ACVBP/R,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
ADE & ATRA,ADE  and  ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE and ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE / ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE + ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE+ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE/ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE & ATRA,ADE & ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
ADE (high-dose Ara-C),HIDAC35,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),ADE (high-dose Ara-C),"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),HIDAC/3/5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),HIDAC37,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),HIDAC-3-5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),HIDAC-3-7,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),ADE,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (high-dose Ara-C),HIDAC/3/7,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),7/3/7,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),7-3-7,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),ADE (standard-dose Ara-C),"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),1035,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),737,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),10/3/5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),10-3-5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),8/3/5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),835,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),ADE,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADE (standard-dose Ara-C),8-3-5,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
ADOC,ADOC,"Advanced or metastatic disease, first-line therapy",Thymoma
APO,APO,Untreated,Anaplastic_large_cell_lymphoma
AT (Taxol),AT (Taxol),Adjuvant chemotherapy,Breast_cancer
ATG (Horse) & Cyclosporine,ATG (Horse) & Cyclosporine,Initial therapy,"Aplastic_anemia,Myelodysplastic_syndrome"
ATG (Horse) monotherapy,ATG (Horse) monotherapy,First-line therapy,Myelodysplastic_syndrome
ATG (Horse) monotherapy,ATG,First-line therapy,Myelodysplastic_syndrome
"ATG (Horse), Cyclosporine, Eltrombopag","ATG (Horse), Cyclosporine, Eltrombopag",Initial therapy,Aplastic_anemia
"ATG (Horse), Cyclosporine, G-CSF","ATG (Horse), Cyclosporine, G-CSF",Initial therapy,Aplastic_anemia
"ATG (Horse), Cyclosporine, Methylprednisolone","ATG (Horse), Cyclosporine, Methylprednisolone",Initial therapy,Aplastic_anemia
"ATG (Horse), Cyclosporine, Sirolimus","ATG (Horse), Cyclosporine, Sirolimus",Initial therapy,Aplastic_anemia
ATG (Rabbit) & Cyclosporine,ATG (Rabbit) & Cyclosporine,Initial therapy,Aplastic_anemia
ATG (Rabbit) monotherapy,ATG (Rabbit) monotherapy,First-line therapy,Myelodysplastic_syndrome
ATG (Rabbit) monotherapy,ATG,First-line therapy,Myelodysplastic_syndrome
ATRA & Danazol,ATRA+Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA + Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA  and  Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA and Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA/Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA / Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Danazol,ATRA & Danazol,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
ATRA & Daunorubicin,ATRA and Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA+Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA/Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA + Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA / Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA  and  Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Daunorubicin,ATRA & Daunorubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA and Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA & Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA+Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA / Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA  and  Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,AIDA,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA + Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA & Idarubicin,ATRA/Idarubicin,Upfront induction therapy,Acute_promyelocytic_leukemia
ATRA monotherapy,ATRA monotherapy,Upfront induction therapy,Acute_promyelocytic_leukemia
"ATRA, Cytarabine, Daunorubicin","ATRA, Cytarabine, Daunorubicin",Upfront induction therapy,Acute_promyelocytic_leukemia
"ATRA, Cytarabine, Idarubicin","ATRA, Cytarabine, Idarubicin",Upfront induction therapy,Acute_promyelocytic_leukemia
"ATRA, Mercaptopurine, Methotrexate","ATRA, Mercaptopurine, Methotrexate",Maintenance after upfront therapy,Acute_promyelocytic_leukemia
AVD,AVD,"Untreated, early-stage favorable (ESF)",Hodgkin_lymphoma
Acalabrutinib monotherapy,Acalabrutinib monotherapy,"Relapsed or refractory, non-randomized or retrospective data","Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Accelerated BEP,Accelerated BEP,Upfront therapy for disseminated disease,Testicular_cancer
Ado-trastuzumab emtansine monotherapy,Ado-trastuzumab emtansine monotherapy,All lines of therapy,ERBB2_(HER2)
Afatinib & Paclitaxel,Afatinib & Paclitaxel,"Advanced or metastatic disease, subsequent lines of therapy",Non-small_cell_lung_cancer
Afatinib monotherapy,Afatinib monotherapy,"Non-small cell lung cancer, EGFR-mutated, all lines of therapy","Head_and_neck_cancer,Non-small_cell_lung_cancer,CNS_carcinoma,Non-small_cell_lung_cancer_EGFR-mutated"
Alectinib monotherapy,Alectinib monotherapy,"Non-small cell lung cancer, ALK-mutated, all lines of therapy","Non-small_cell_lung_cancer_ALK-positive,CNS_carcinoma"
Alemtuzumab & Methylprednisolone,Alemtuzumab & Methylprednisolone,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Alemtuzumab & Rituximab,Alemtuzumab & Rituximab,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Alemtuzumab monotherapy,Alemtuzumab monotherapy,Relapsed or refractory,"Waldenstrom_macroglobulinemia,Adult_T-cell_leukemia-lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Myelodysplastic_syndrome,Hypereosinophilic_syndrome,Cutaneous_T-cell_lymphoma,Autoimmune_cytopenias"
Altretamine monotherapy,Altretamine monotherapy,Maintenance after first-line therapy,Ovarian_cancer
Amrubicin monotherapy,Amrubicin monotherapy,"Advanced or metastatic disease, subsequent lines of therapy","Non-small_cell_lung_cancer,Small_cell_lung_cancer"
Anagrelide monotherapy,Anagrelide monotherapy,"Relapsed, refractory, or intolerant",Polycythemia_vera
Anakinra monotherapy,Anakinra monotherapy,"HHV-8-negative/""Idiopathic"" multicentric Castleman disease, all lines of therapy",Castleman_disease
Apixaban monotherapy,Apixaban monotherapy,VTE primary prophylaxis,Venous_thromboembolism_(VTE)
Argatroban monotherapy,Argatroban monotherapy,All lines of therapy,"Venous_thromboembolism_(VTE),Heparin-induced_thrombocytopenia_(HIT)"
Arsenic trioxide & ATRA,Arsenic trioxide & ATRA,Upfront induction therapy,Acute_promyelocytic_leukemia
Arsenic trioxide & Chlorambucil,Arsenic trioxide & Chlorambucil,"Relapsed or refractory, non-randomized or retrospective data",Mantle_cell_lymphoma
Arsenic trioxide & Idarubicin,Arsenic trioxide & Idarubicin,"Relapsed or refractory, salvage induction therapy",Acute_promyelocytic_leukemia
Arsenic trioxide monotherapy,Arsenic trioxide monotherapy,Upfront induction therapy,Acute_promyelocytic_leukemia
"Arsenic trioxide, ATRA, Gemtuzumab ozogamicin","Arsenic trioxide, ATRA, Gemtuzumab ozogamicin",Upfront induction therapy,Acute_promyelocytic_leukemia
"Arsenic trioxide, ATRA, Idarubicin","Arsenic trioxide, ATRA, Idarubicin",Upfront induction therapy,Acute_promyelocytic_leukemia
"Arsenic trioxide, then ATRA & Daunorubicin","Arsenic trioxide, then ATRA & Daunorubicin",Consolidation after upfront therapy,Acute_promyelocytic_leukemia
AspaMetDex,AspaMetDex,Relapsed or refractory,Extranodal_NKT-cell_lymphoma_nasal_type
Aspirin & Anagrelide,Aspirin & Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin + Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin+Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin and Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin  and  Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin / Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Anagrelide,Aspirin/Anagrelide,First-line therapy,Essential_thrombocythemia
Aspirin & Hydroxyurea,Aspirin & Hydroxyurea,First-line therapy,Essential_thrombocythemia
Aspirin monotherapy,Aspirin monotherapy,VTE primary prophylaxis,Venous_thromboembolism_(VTE)
Atezolizumab & Bevacizumab,Atezolizumab & Bevacizumab,Maintenance after first-line therapy,Non-small_cell_lung_cancer
Atezolizumab monotherapy,Atezolizumab monotherapy,"Locally advanced or metastatic disease, first-line","Non-small_cell_lung_cancer,Bladder_cancer,Small_cell_lung_cancer"
Axicabtagene ciloleucel monotherapy,Axicabtagene ciloleucel monotherapy,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
Axitinib & TACE,Axitinib & TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib  and  TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib and TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib + TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib / TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib/TACE,Local therapy,Hepatocellular_carcinoma
Axitinib & TACE,Axitinib+TACE,Local therapy,Hepatocellular_carcinoma
Axitinib monotherapy,Axitinib monotherapy,"Metastatic disease, first-line","Renal_cell_carcinoma,Thyroid_cancer"
Azacitidine & Gemtuzumab ozogamicin,Azacitidine & Gemtuzumab ozogamicin,Consolidation after upfront therapy,Acute_myeloid_leukemia
Azacitidine & Lenalidomide,Azacitidine & Lenalidomide,First-line therapy,"Chronic_myelomonocytic_leukemia,Myelodysplastic_syndrome"
Azacitidine & Sorafenib,Azacitidine & Sorafenib,"Relapsed or refractory, further lines of therapy",Acute_myeloid_leukemia_FLT3-positive
Azacitidine & Vorinostat,Azacitidine & Vorinostat,First-line therapy,"Chronic_myelomonocytic_leukemia,Myelodysplastic_syndrome"
Azacitidine monotherapy,Azacitidine monotherapy,"First-line induction therapy, older or ""unfit"" patients","Chronic_myelomonocytic_leukemia,Acute_myeloid_leukemia,Myelodysplastic_syndrome"
BBD,BBD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
BCHOP,BCHOP,"Relapsed or refractory, randomized data",Mantle_cell_lymphoma
BCNU/TT,BCNUTT,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
BCNU/TT,BCNU/TT,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"BCNU/TT, then auto HSCT",BCNUTT,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"BCNU/TT, then auto HSCT","BCNU/TT, then auto HSCT",Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"BCNU/TT, then auto HSCT",BCNU/TT,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
BDR,BORID,"Relapsed or refractory, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma"
BDR,BDR,"Relapsed or refractory, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma"
BEAC,BEAC,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
BEACOPP,BEACOPP,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
BEACOPP-14,BEACOPP14,"Untreated, advanced stage",Hodgkin_lymphoma
BEACOPP-14,BEACOPP/14,"Untreated, advanced stage",Hodgkin_lymphoma
BEACOPP-14,BEACOPP-14,"Untreated, advanced stage",Hodgkin_lymphoma
BEAM,BEAM,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
"BEAM, then auto HSCT","BEAM, then auto HSCT",Consolidation and/or maintenance after upfront therapy,"HIV-associated_lymphoma,CNS_lymphoma"
"BEAM, then auto HSCT",BEAM,Consolidation and/or maintenance after upfront therapy,"HIV-associated_lymphoma,CNS_lymphoma"
BEP,PEB,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Testicular_cancer"
BEP,BEP,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Testicular_cancer"
BFR,BFR,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
BLD,BLD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
BMP,MPB,Metastatic or unresectable disease,Penile_cancer
BMP,BMP,Metastatic or unresectable disease,Penile_cancer
BO,BO,Upfront therapy for disseminated disease,Testicular_cancer
BR,R-B,"First-line therapy, randomized data","Waldenstrom_macroglobulinemia,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Cold_agglutinin_disease,Marginal_zone_lymphoma,Hairy_cell_leukemia"
BR,R/B,"First-line therapy, randomized data","Waldenstrom_macroglobulinemia,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Cold_agglutinin_disease,Marginal_zone_lymphoma,Hairy_cell_leukemia"
BR,BR,"First-line therapy, randomized data","Waldenstrom_macroglobulinemia,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Cold_agglutinin_disease,Marginal_zone_lymphoma,Hairy_cell_leukemia"
BR & Ibrutinib,BR / Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR + Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR and Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR & Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR/Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,IBR,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR+Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Ibrutinib,BR  and  Ibrutinib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR/Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR / Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR + Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR & Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR and Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR+Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BR & Idelalisib,BR  and  Idelalisib,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
BTD,BTD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
BV-CHP,BVCHP,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
BV-CHP,BV/CHP,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
BV-CHP,BV-CHP,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
BVB,BVB,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
BVR,BVR,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
BVR,VBR,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
BeEAM,BeEAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
BeGEV,BeGEV,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
BeRT,BeRT,"Relapsed or refractory, non-randomized or retrospective data",Mantle_cell_lymphoma
Belinostat monotherapy,Belinostat monotherapy,Relapsed or refractory,"Cutaneous_T-cell_lymphoma,Peripheral_T-cell_lymphoma"
Belotecan & Cisplatin,Belotecan & Cisplatin,"Extensive stage, induction",Small_cell_lung_cancer
Bendamustine & Obinutuzumab,G-B,"First-line therapy, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Bendamustine & Obinutuzumab,Bendamustine & Obinutuzumab,"First-line therapy, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Bendamustine & Obinutuzumab,G/B,"First-line therapy, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Bendamustine & Ofatumumab,BendOfa,"Relapsed or refractory, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Bendamustine & Ofatumumab,Bendamustine & Ofatumumab,"Relapsed or refractory, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Bendamustine monotherapy,Bendamustine monotherapy,"Low-dose conditioning regimens for cellular therapy, all lines of therapy","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Peripheral_T-cell_lymphoma,Diffuse_large_B-cell_lymphoma,Autologous_HSCT,Hodgkin_lymphoma,Small_cell_lung_cancer,Cutaneous_T-cell_lymphoma,Marginal_zone_lymphoma,Transformed_lymphoma"
Betrixaban monotherapy,Betrixaban monotherapy,VTE primary prophylaxis,Venous_thromboembolism_(VTE)
Bevacizumab & RT,Bevacizumab / RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab & RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab  and  RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab/RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab+RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab and RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & RT,Bevacizumab + RT,"Adjuvant therapy, standard patients",Glioblastoma
Bevacizumab & Rituximab,Bevacizumab & Rituximab,"Relapsed or refractory, randomized data",Follicular_lymphoma
Bevacizumab monotherapy,Bevacizumab monotherapy,"Recurrent disease, salvage therapy","Hepatocellular_carcinoma,Non-small_cell_lung_cancer,Colon_cancer,Ovarian_cancer,Cervical_cancer,Renal_cell_carcinoma,Glioblastoma,Breast_cancer,Anaplastic_glioma,Small_cell_lung_cancer,Endometrial_cancer,Vascular_sarcoma"
Bexarotene & Pralatrexate,Bexarotene & Pralatrexate,Relapsed or refractory,Cutaneous_T-cell_lymphoma
Bexarotene monotherapy,Bexarotene monotherapy,Relapsed or refractory,Cutaneous_T-cell_lymphoma
Binimetinib & Encorafenib,Binimetinib & Encorafenib,"Advanced or metastatic disease, BRAF inhibitor-naive",Melanoma_BRAF-mutated
Binimetinib monotherapy,Binimetinib monotherapy,"Advanced or metastatic disease, TKI-naive",Melanoma_NRAS-mutated
Bivalirudin monotherapy,Bivalirudin monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Bleomycin & Cisplatin,Bleomycin & Cisplatin,Neoadjuvant chemotherapy,"Cutaneous_basal_cell_carcinoma,Cutaneous_squamous_cell_carcinoma"
Blinatumomab monotherapy,Blinatumomab monotherapy,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
Bortezomib & Cyclophosphamide,Bortezomib & Cyclophosphamide,Maintenance after second-line therapy,Multiple_myeloma_relapsedrefractory
Bortezomib & Dexamethasone,Bortezomib & Dexamethasone,First-line therapy (including transplant ineligible),"Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction,Light-chain_(AL)_amyloidosis"
Bortezomib & Doxorubicin liposomal,Bortezomib & Doxorubicin liposomal,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Bortezomib & Melphalan,Bor/HDM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bortezomib & Melphalan,BorHDM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bortezomib & Melphalan,Bortezomib & Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bortezomib & Melphalan,Bor-HDM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"Bortezomib & Melphalan, then auto HSCT","Bortezomib & Melphalan, then auto HSCT",Consolidation after first-line therapy,Light-chain_(AL)_amyloidosis
Bortezomib & Panobinostat,Bortezomib & Panobinostat,"Relapsed or refractory, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
Bortezomib & Vorinostat,Bortezomib & Vorinostat,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Bortezomib monotherapy,Bortezomib monotherapy,"HHV-8-negative/""Idiopathic"" multicentric Castleman disease, all lines of therapy","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Multiple_myeloma_relapsedrefractory,Mantle_cell_lymphoma,Multiple_myeloma_consolidation_and_maintenance,Light-chain_(AL)_amyloidosis,Marginal_zone_lymphoma,Castleman_disease"
"Bortezomib, Thalidomide, Dexamethasone, Panobinostat","Bortezomib, Thalidomide, Dexamethasone, Panobinostat","Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Bortezomib-HyperCAD,Bortezomib-HyperCAD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Bosutinib monotherapy,Bosutinib monotherapy,Relapsed or refractory,"Chronic_myelogenous_leukemia,B-cell_acute_lymphoblastic_leukemia_Ph-positive"
Brentuximab vedotin & Dacarbazine,Brentuximab vedotin & Dacarbazine,"Untreated, elderly",Hodgkin_lymphoma
Brentuximab vedotin & Nivolumab,Brentuximab vedotin & Nivolumab,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Brentuximab vedotin monotherapy,Brentuximab vedotin monotherapy,"Relapsed or refractory, salvage therapy","Peripheral_T-cell_lymphoma,Diffuse_large_B-cell_lymphoma,Hodgkin_lymphoma,Cutaneous_T-cell_lymphoma,Mediastinal_gray-zone_lymphoma,Anaplastic_large_cell_lymphoma"
Brigatinib monotherapy,Brigatinib monotherapy,"Advanced or metastatic disease, ALK inhibitor-naive",Non-small_cell_lung_cancer_ALK-positive
Bu/TT,Bu/TT,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bu/TT,BuTT,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"Bu/TT, then auto HSCT",Bu/TT,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"Bu/TT, then auto HSCT","Bu/TT, then auto HSCT",Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"Bu/TT, then auto HSCT",BuTT,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
Bu/TT/Cy,TBC,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bu/TT/Cy,BuTTCy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Bu/TT/Cy,Bu/TT/Cy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"Bu/TT/Cy, then auto HSCT","Bu/TT/Cy, then auto HSCT",Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"Bu/TT/Cy, then auto HSCT",BuTTCy,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
"Bu/TT/Cy, then auto HSCT",Bu/TT/Cy,Consolidation and/or maintenance after upfront therapy,CNS_lymphoma
BuCyTBI,BuCyTBI,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
Busulfan & Cyclophosphamide,Busulfan & Cyclophosphamide,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Busulfan & Cyclophosphamide,BuCy,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Busulfan & Fludarabine,BuFlu,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
Busulfan & Fludarabine,Busulfan & Fludarabine,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
Busulfan & Fludarabine,FluBu,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
Busulfan & Fludarabine,Flu/Bu,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
Busulfan & Melphalan,Busulfan + Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan+Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan / Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan and Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan & Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,BuMel,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan/Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan & Melphalan,Busulfan  and  Melphalan,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Busulfan monotherapy,Busulfan monotherapy,"Chronic phase, relapsed or refractory",Chronic_myelogenous_leukemia
C-BOP,C-BOP,Upfront therapy for disseminated disease,Testicular_cancer
C-BOP,C/BOP,Upfront therapy for disseminated disease,Testicular_cancer
C-BOP,CBOP,Upfront therapy for disseminated disease,Testicular_cancer
C-MOPP,C/MOPP,Consolidation after upfront therapy,Hodgkin_lymphoma
C-MOPP,C-MOPP,Consolidation after upfront therapy,Hodgkin_lymphoma
C-MOPP,CMOPP,Consolidation after upfront therapy,Hodgkin_lymphoma
C-MOPP,COPP,Consolidation after upfront therapy,Hodgkin_lymphoma
C-MOPP/ABV,C-MOPP/ABV,"Untreated, advanced stage",Hodgkin_lymphoma
C-MOPP/ABV,CMOPP/ABV,"Untreated, advanced stage",Hodgkin_lymphoma
C-MOPP/ABV,C/MOPP/ABV,"Untreated, advanced stage",Hodgkin_lymphoma
CAD & G-CSF,CAD+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAD & G-CSF,CAD & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CAPIRI,CAPIRI,"Advanced or metastatic disease, first-line","Esophageal_cancer,Colon_cancer"
CAPIRI,XELIRI,"Advanced or metastatic disease, first-line","Esophageal_cancer,Colon_cancer"
CAPIRI,CapeIRI,"Advanced or metastatic disease, first-line","Esophageal_cancer,Colon_cancer"
CAPIRI-Bev,XELIRI-Bev,"Advanced or metastatic disease, first-line",Colon_cancer
CAPIRI-Bev,CAPIRI/Bev,"Advanced or metastatic disease, first-line",Colon_cancer
CAPIRI-Bev,CAPIRI-Bev,"Advanced or metastatic disease, first-line",Colon_cancer
CAPIRI-Bev,CAPIRIBev,"Advanced or metastatic disease, first-line",Colon_cancer
CAPIRI-Bev,XELIRIBev,"Advanced or metastatic disease, first-line",Colon_cancer
CAPIRI-Bev,XELIRI/Bev,"Advanced or metastatic disease, first-line",Colon_cancer
CBV,CBV,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CBV-Mx,CBVMx,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CBV-Mx,CBV-Mx,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CBV-Mx,CBV/Mx,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CC,CC,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
CF & Trastuzumab,CF+Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF and Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF/Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF & Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF  and  Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF / Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CF & Trastuzumab,CF + Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CFAR,CFAR,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
CHOEP,CHOEP,Untreated,Anaplastic_large_cell_lymphoma
CHOEP-14,CHOEP/14,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOEP-14,CHOEP-14,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOEP-14,CHOEP14,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP,CHOP,Untreated,"HIV-associated_lymphoma,Mantle_cell_lymphoma,Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
CHOP & Everolimus,CHOP/Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP & Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP + Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP and Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP  and  Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP / Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP & Everolimus,CHOP+Everolimus,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-14,CHOPDI,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,CHOP-DI,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,CHOP14,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,I-CHOP,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,ICHOP,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,CHOP-14,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,CHOP/DI,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,I/CHOP,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-14,CHOP/14,Untreated,Adult_T-cell_leukemia-lymphoma
CHOP-AL,CHOP-AL,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-AL,CHOPAL,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-AL,CHOPC,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-AL,CHOP/C,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-AL,CHOP-C,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHOP-AL,CHOP/AL,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
CHUT,CHUT,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CIA,CIA,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
CIM,CIM,Adjuvant therapy,Endometrial_cancer
CISCA,CISCA,"Locally advanced or metastatic disease, first-line",Bladder_cancer
CLAG,CLAG,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
CLAG-M,CLAGM,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
CLAG-M,CLAG-M,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
CLAG-M,CLAG/M,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
CLARA,CLARA,Consolidation after upfront therapy,Acute_myeloid_leukemia
CLF,PLF,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
CLF,CLF,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
CMC,CMC,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
CMED,CMED,"Untreated, randomized data",Peripheral_T-cell_lymphoma
CMF,CMF,Adjuvant chemotherapy,Breast_cancer_triple_negative
CODOX-M,CODOXM,Upfront therapy,HIV-associated_lymphoma
CODOX-M,CODOX-M,Upfront therapy,HIV-associated_lymphoma
CODOX-M,CODOX/M,Upfront therapy,HIV-associated_lymphoma
CODOX-M/IVAC,CODOX-M/IVAC,Upfront therapy,HIV-associated_lymphoma
COPDAC,COPDAC,Consolidation after upfront therapy,Hodgkin_lymphoma
CPD,CPD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
CPD,KPD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
CPR,CPR,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
CPX-351 monotherapy,CPX-351 monotherapy,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
CPX-351 monotherapy,CPX/351,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
CPX-351 monotherapy,CPX351,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
CPX-351 monotherapy,CPX-351,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
CRD (Cyclophosphamide),CRD (Cyclophosphamide),"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
CRD (Cyclophosphamide),CRD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
CRd (Carfilzomib),KRd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
CRd (Carfilzomib),CRd (Carfilzomib),"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
CRd (Carfilzomib),CRd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
CRd (Cyclophosphamide),CRd (Cyclophosphamide),First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
CRd (Cyclophosphamide),RdC,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
CRd (Cyclophosphamide),LDC,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
CRd (Cyclophosphamide),CRd,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
CTCb,CTCb,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
CTD,CTD,First-line therapy (including transplant ineligible),"Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction,Light-chain_(AL)_amyloidosis"
CVAD,CVAD,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
CVD (Vinblastine),CVD (Vinblastine),Metastatic or unresectable disease,Melanoma
CVD (Vinblastine),CVD,Metastatic or unresectable disease,Melanoma
CVD (Vindesine),CVD (Vindesine),Metastatic or unresectable disease,Melanoma
CVD (Vindesine),CVD,Metastatic or unresectable disease,Melanoma
CVP,CVP,"First-line therapy, pre-phase",Mantle_cell_lymphoma
CX,CX,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX+Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX + Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX/Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX & Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX / Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX  and  Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX & Trastuzumab,CX and Trastuzumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
CX-C,CX/C,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CX-C,CXC,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CX-C,CX-C,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
CYM,CYM,"Upfront therapy, randomized data",CNS_lymphoma
CYVE,CYVE,Consolidation after salvage therapy,"CNS_lymphoma,Autologous_HSCT,Acute_myeloid_leukemia"
CYVE & G-CSF,CYVE + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CYVE & G-CSF,CYVE+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
CaRD,CaRD,"First-line therapy, non-randomized or retrospective data",Waldenstrom_macroglobulinemia
Cabozantinib & Erlotinib,Cabozantinib & Erlotinib,"Advanced or metastatic disease, subsequent lines of therapy",Non-small_cell_lung_cancer
Cabozantinib monotherapy,Cabozantinib monotherapy,Subsequent lines of therapy,"Hepatocellular_carcinoma,Non-small_cell_lung_cancer,Renal_cell_carcinoma,Thyroid_cancer,Prostate_cancer"
CapeOx,XELOX,Adjuvant therapy,"Hepatocellular_carcinoma,Colon_cancer,Gastric_cancer,Esophageal_cancer,Rectal_cancer,Pancreatic_cancer"
CapeOx,CapeOX,Adjuvant therapy,"Hepatocellular_carcinoma,Colon_cancer,Gastric_cancer,Esophageal_cancer,Rectal_cancer,Pancreatic_cancer"
CapeOx,CAPOX,Adjuvant therapy,"Hepatocellular_carcinoma,Colon_cancer,Gastric_cancer,Esophageal_cancer,Rectal_cancer,Pancreatic_cancer"
CapeOx,CapeOx,Adjuvant therapy,"Hepatocellular_carcinoma,Colon_cancer,Gastric_cancer,Esophageal_cancer,Rectal_cancer,Pancreatic_cancer"
CapeOx & Bevacizumab,CapeOx/Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx+Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX  and  Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX+Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX+Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX/Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX + Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX & Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX + Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX and Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx and Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx  and  Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX and Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX  and  Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx / Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CAPOX-B,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,XELOX / Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx & Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CAPOXB,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CAPOX/B,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX & Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX/Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOX / Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Bevacizumab,CapeOx + Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
CapeOx & Panitumumab,CapeOx and Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx  and  Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx / Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx & Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx+Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx + Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
CapeOx & Panitumumab,CapeOx/Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
"CapeOx, Cetuximab, RT","CapeOX, Cetuximab, RT",Neoadjuvant therapy,Rectal_cancer
"CapeOx, Cetuximab, RT","CapeOx, Cetuximab, RT",Neoadjuvant therapy,Rectal_cancer
Capecitabine & Bevacizumab,Capecitabine & Bevacizumab,"Advanced or metastatic disease, first-line","Hepatocellular_carcinoma,Colon_cancer"
Capecitabine & Erlotinib,Capecitabine & Erlotinib,"Metastatic disease, refractory",Pancreatic_cancer
Capecitabine & Gemcitabine,Capecitabine & Gemcitabine,Adjuvant therapy,"Cholangiocarcinoma,Pancreatic_cancer,Thymoma"
Capecitabine & Gemcitabine,GemCap,Adjuvant therapy,"Cholangiocarcinoma,Pancreatic_cancer,Thymoma"
Capecitabine & Ixabepilone,Capecitabine & Ixabepilone,"Metastatic disease, subsequent lines of therapy",Breast_cancer_triple_negative
Capecitabine & Lapatinib,Capecitabine & Lapatinib,"Breast cancer, HER2-positive, all lines of therapy",CNS_carcinoma
Capecitabine & Mitomycin,Capecitabine & Mitomycin,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
Capecitabine & RT,Capecitabine  and  RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine/RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine and RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine & RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine+RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine / RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & RT,Capecitabine + RT,Neoadjuvant therapy,Rectal_cancer
Capecitabine & Temozolomide,Capecitabine & Temozolomide,All lines of therapy,Pancreatic_NET
Capecitabine & Trastuzumab,Capecitabine & Trastuzumab,"Breast cancer, HER2-positive, all lines of therapy",CNS_carcinoma
Capecitabine monotherapy,Capecitabine monotherapy,Adjuvant chemotherapy,"Hepatocellular_carcinoma,Colon_cancer,Gastric_cancer,Cholangiocarcinoma,Breast_cancer,Rectal_cancer,Pancreatic_cancer"
"Capecitabine, Carboplatin, Paclitaxel, RT","Capecitabine, Carboplatin, Paclitaxel, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Cisplatin, RT","Capecitabine, Cisplatin, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Docetaxel, Oxaliplatin, RT","Capecitabine, Docetaxel, Oxaliplatin, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Docetaxel, RT","Capecitabine, Docetaxel, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Mitomycin, RT","Capecitabine, Mitomycin, RT",Definitive chemoradiotherapy for locally advanced disease,Anal_cancer
"Capecitabine, Oxaliplatin, RT","Capecitabine, Oxaliplatin, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Paclitaxel, RT","Capecitabine, Paclitaxel, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Capecitabine, Sorafenib, RT","Capecitabine, Sorafenib, RT",Neoadjuvant therapy,Rectal_cancer
"Capecitabine, then Capecitabine & RT, then Capecitabine","Capecitabine, then Capecitabine & RT, then Capecitabine",Adjuvant chemoradiotherapy,Rectal_cancer
Carboplatin & Bevacizumab,Carboplatin & Bevacizumab,"Recurrent disease, salvage therapy","Anaplastic_glioma,Glioblastoma"
Carboplatin & Docetaxel,Carboplatin & Docetaxel,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Non-small_cell_lung_cancer,Ovarian_cancer,Cervical_cancer,Prostate_cancer,Head_and_neck_cancer,Breast_cancer_triple_negative"
Carboplatin & Doxorubicin liposomal,Carboplatin & Doxorubicin liposomal,"Chemotherapy for advanced, recurrent, or metastatic disease","Ovarian_cancer,Endometrial_cancer"
Carboplatin & Etoposide,Carboplatin & Etoposide,"Advanced or metastatic disease, first-line","Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Carboplatin & Etoposide, then auto HSCT",TI/CE,Consolidation after salvage therapy,Testicular_cancer
"Carboplatin & Etoposide, then auto HSCT",TICE,Consolidation after salvage therapy,Testicular_cancer
"Carboplatin & Etoposide, then auto HSCT","Carboplatin & Etoposide, then auto HSCT",Consolidation after salvage therapy,Testicular_cancer
"Carboplatin & Etoposide, then auto HSCT",TI-CE,Consolidation after salvage therapy,Testicular_cancer
Carboplatin & Fluorouracil,Carboplatin & Fluorouracil,"Recurrent or metastatic disease, first-line therapy",Head_and_neck_cancer
Carboplatin & Gemcitabine,Carboplatin & Gemcitabine,"Metastatic disease, first-line therapy","Ovarian_cancer,Breast_cancer_triple_negative,Non-small_cell_lung_cancer"
Carboplatin & Gemcitabine/Erlotinib,Carboplatin & Gemcitabine/Erlotinib,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Carboplatin & Ifosfamide,Carboplatin & Ifosfamide,Adjuvant therapy,Cervical_cancer
Carboplatin & Irinotecan,Carboplatin & Irinotecan,"Extensive stage, induction",Small_cell_lung_cancer
Carboplatin & Paclitaxel,Carboplatin & Paclitaxel,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Non-small_cell_lung_cancer,Gastric_cancer,Ovarian_cancer,Bladder_cancer,Cervical_cancer,Endometrial_cancer,Esophageal_cancer,Prostate_cancer,Breast_cancer_triple_negative,Thymoma,Melanoma"
Carboplatin & Pemetrexed,Carboplatin & Pemetrexed,"Advanced or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Mesothelioma"
Carboplatin & RT,Carboplatin / RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin+RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin + RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin & RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin and RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin  and  RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & RT,Carboplatin/RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Nasopharyngeal_carcinoma,Cervical_cancer,Non-small_cell_lung_cancer"
Carboplatin & Teniposide,Carboplatin & Teniposide,"Recurrent or progressive, non-curative therapy",Low-grade_glioma
Carboplatin & Vincristine,Carboplatin & Vincristine,Adjuvant therapy,Low-grade_glioma
Carboplatin & Vinorelbine,Carboplatin & Vinorelbine,"Advanced or metastatic disease, first-line",Non-small_cell_lung_cancer
Carboplatin & nab-Paclitaxel,Carboplatin & nab-Paclitaxel,Neoadjuvant chemotherapy,"Breast_cancer_triple_negative,Non-small_cell_lung_cancer,Melanoma"
Carboplatin monotherapy,Carboplatin monotherapy,"Persistent, recurrent, or metastatic disease, first-line therapy","Ovarian_cancer,Cervical_cancer,Testicular_cancer,Low-grade_glioma,Endometrial_cancer"
"Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine","Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine",Adjuvant therapy,Medulloblastoma
"Carboplatin, Docetaxel, Fluorouracil","Carboplatin, Docetaxel, Fluorouracil",Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
"Carboplatin, Etoposide, Bevacizumab","Carboplatin, Etoposide, Bevacizumab","Extensive stage, induction",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP  and  RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT","Carboplatin, Etoposide, RT","Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP+RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP / RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP/RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP & RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP + RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EP and RT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Etoposide, RT",EPRT,"Limited stage, definitive chemoradiotherapy",Small_cell_lung_cancer
"Carboplatin, Fluorouracil, Cetuximab","Carboplatin, Fluorouracil, Cetuximab","Recurrent or metastatic disease, first-line therapy",Head_and_neck_cancer
"Carboplatin, Fluorouracil, Cetuximab, RT","Carboplatin, Fluorouracil, Cetuximab, RT","Locally advanced disease, definitive therapy",Head_and_neck_cancer
"Carboplatin, Fluorouracil, RT","Carboplatin, Fluorouracil, RT",Neoadjuvant chemoradiotherapy,"Esophageal_cancer,Head_and_neck_cancer"
"Carboplatin, Gemcitabine, Bevacizumab","Carboplatin, Gemcitabine, Bevacizumab","Second-line therapy for relapsed or recurrent disease, platinum-sensitive",Ovarian_cancer
"Carboplatin, Olaparib, Paclitaxel","Carboplatin, Olaparib, Paclitaxel","Second-line therapy for relapsed or recurrent disease, platinum-sensitive",Ovarian_cancer
"Carboplatin, Paclitaxel, Bevacizumab",B / CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",B&CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab","Carboplatin, Paclitaxel, Bevacizumab","Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",B+CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",PacCBev,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",B & CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",B/CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",B and CP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Bevacizumab",BCP,"Advanced or metastatic disease, first-line","Ovarian_cancer,Non-small_cell_lung_cancer"
"Carboplatin, Paclitaxel, Pembrolizumab","Carboplatin, Paclitaxel, Pembrolizumab","Advanced or metastatic disease, first-line, squamous",Non-small_cell_lung_cancer
"Carboplatin, Paclitaxel, RT","Carboplatin, Paclitaxel, RT",Neoadjuvant chemoradiotherapy,"Esophageal_cancer,Non-small_cell_lung_cancer,Head_and_neck_cancer"
"Carboplatin, Pemetrexed, Bevacizumab","Carboplatin, Pemetrexed, Bevacizumab","Advanced or metastatic disease, first-line, nonsquamous",Non-small_cell_lung_cancer
"Carboplatin, Pemetrexed, Bevacizumab",PemCBev,"Advanced or metastatic disease, first-line, nonsquamous",Non-small_cell_lung_cancer
"Carboplatin, Vinorelbine, RT","Carboplatin, Vinorelbine, RT",Definitive therapy for locally advanced disease,Non-small_cell_lung_cancer
"Carboplatin, nab-Paclitaxel, Pembrolizumab","Carboplatin, nab-Paclitaxel, Pembrolizumab","Advanced or metastatic disease, first-line, squamous",Non-small_cell_lung_cancer
Carfilzomib & Dexamethasone,Carfilzomib & Dexamethasone,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Carfilzomib & Panobinostat,Carfilzomib & Panobinostat,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Carfilzomib monotherapy,Carfilzomib monotherapy,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Carmustine & RT,BCNURT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine + RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine and RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine+RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU+RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine  and  RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine / RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU and RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine & RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU / RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU + RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU  and  RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,Carmustine/RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU & RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine & RT,BCNU/RT,"Adjuvant therapy, standard patients",Glioblastoma
Carmustine monotherapy,Carmustine monotherapy,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Cemiplimab monotherapy,Cemiplimab monotherapy,"Advanced or metastatic disease, all lines of therapy",Cutaneous_squamous_cell_carcinoma
Ceritinib monotherapy,Ceritinib monotherapy,"Non-small cell lung cancer, ALK-mutated, all lines of therapy","Non-small_cell_lung_cancer_ROS1-positive,Non-small_cell_lung_cancer_ALK-positive,CNS_carcinoma"
Cetuximab & RT,Cetuximab and RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab / RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab+RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab/RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab & RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab  and  RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab & RT,Cetuximab + RT,"Locally advanced disease, definitive therapy",Head_and_neck_cancer
Cetuximab monotherapy,Cetuximab monotherapy,Maintenance after first-line therapy,"Cutaneous_squamous_cell_carcinoma,Colon_cancer_KRAS_wild-type,Esophageal_cancer,Head_and_neck_cancer"
Chidamide monotherapy,Chidamide monotherapy,"Relapsed or refractory, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
ChlVPP,ChlVPP,"Untreated, elderly",Hodgkin_lymphoma
ChlVPP/EVA,ChlVPP/EVA,"Untreated, elderly",Hodgkin_lymphoma
Chlorambucil & Obinutuzumab,Chlorambucil & Obinutuzumab,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Chlorambucil & Obinutuzumab,GClb,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Chlorambucil & Ofatumumab,Chlorambucil & Ofatumumab,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Chlorambucil & Rituximab,Chlorambucil & Rituximab,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Chlorambucil & Rituximab,CLB-R,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Chlorambucil & Rituximab,CLBR,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Chlorambucil & Rituximab,RClb,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Chlorambucil & Rituximab,CLB/R,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Chlorambucil monotherapy,Chlorambucil monotherapy,"Advanced disease, first-line therapy, randomized data","Waldenstrom_macroglobulinemia,Marginal_zone_lymphoma,Follicular_lymphoma"
Cisplatin & Cetuximab,Cisplatin & Cetuximab,"Recurrent or metastatic disease, first-line therapy",Head_and_neck_cancer
Cisplatin & Dacarbazine,Cisplatin & Dacarbazine,Metastatic or unresectable disease,Melanoma
Cisplatin & Docetaxel,Cisplatin & Docetaxel,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Non-small_cell_lung_cancer,Gastric_cancer,Esophageal_cancer,Head_and_neck_cancer,Breast_cancer_triple_negative"
Cisplatin & Doxorubicin,Cisplatin & Doxorubicin,"Advanced or metastatic disease, all lines of therapy","Cutaneous_basal_cell_carcinoma,Osteosarcoma,Endometrial_cancer,Cutaneous_squamous_cell_carcinoma,Hepatoblastoma"
Cisplatin & Epirubicin,CIS/EPI,"Relapsed or refractory, salvage therapy",Testicular_cancer
Cisplatin & Epirubicin,CISEPI,"Relapsed or refractory, salvage therapy",Testicular_cancer
Cisplatin & Epirubicin,CIS-EPI,"Relapsed or refractory, salvage therapy",Testicular_cancer
Cisplatin & Epirubicin,Cisplatin & Epirubicin,"Relapsed or refractory, salvage therapy",Testicular_cancer
Cisplatin & Etoposide,Cisplatin & Etoposide,Neoadjuvant induction therapy,"Non-small_cell_lung_cancer,Esophageal_cancer,Testicular_cancer,Small_cell_lung_cancer,Thymoma,Low-grade_glioma"
Cisplatin & Fluorouracil,Cisplatin & Fluorouracil,Neoadjuvant induction therapy,"Penile_cancer,Gastric_cancer,Nasopharyngeal_carcinoma,Esophageal_cancer,Head_and_neck_cancer"
Cisplatin & Gemcitabine,Cisplatin & Gemcitabine,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Non-small_cell_lung_cancer,Ovarian_cancer,Bladder_cancer,Cervical_cancer,Mesothelioma,Cholangiocarcinoma,Breast_cancer_triple_negative,Pancreatic_cancer"
Cisplatin & Gemcitabine/Erlotinib,Cisplatin & Gemcitabine/Erlotinib,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Cisplatin & Ifosfamide,Cisplatin & Ifosfamide,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
Cisplatin & Irinotecan,Cisplatin & Irinotecan,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Non-small_cell_lung_cancer,Penile_cancer,Esophageal_cancer,Small_cell_lung_cancer"
Cisplatin & Mitomycin,Cisplatin & Mitomycin,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
Cisplatin & Paclitaxel,Cisplatin & Paclitaxel,Neoadjuvant chemotherapy,"Non-small_cell_lung_cancer,Ovarian_cancer,Cutaneous_basal_cell_carcinoma,Cervical_cancer,Esophageal_cancer,Head_and_neck_cancer,Endometrial_cancer"
Cisplatin & Pemetrexed,Cisplatin & Pemetrexed,"Advanced or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Mesothelioma"
Cisplatin & RT,Cisplatin / RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin and RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin  and  RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin + RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin+RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin & RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & RT,Cisplatin/RT,Induction chemoradiotherapy,"Vulvar_cancer,Non-small_cell_lung_cancer,Nasopharyngeal_carcinoma,Bladder_cancer,Cervical_cancer,Extranodal_NKT-cell_lymphoma_nasal_type,Head_and_neck_cancer"
Cisplatin & Raltitrexed,Cisplatin & Raltitrexed,"Advanced or metastatic disease, first-line therapy",Mesothelioma
Cisplatin & S-1,Cisplatin + S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin & S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin / S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin  and  S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin/S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin+S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & S-1,Cisplatin and S-1,"Metastatic or locally advanced disease, first-line",Gastric_cancer
Cisplatin & Topotecan,Cisplatin & Topotecan,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
Cisplatin & Vinblastine,Cisplatin & Vinblastine,Adjuvant therapy,Non-small_cell_lung_cancer
Cisplatin & Vindesine,Cisplatin & Vindesine,Adjuvant therapy,Non-small_cell_lung_cancer
Cisplatin & Vinorelbine,Cisplatin & Vinorelbine,"Persistent, recurrent, or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Cervical_cancer"
Cisplatin monotherapy,Cisplatin monotherapy,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Bladder_cancer,Cervical_cancer,Mesothelioma,Soft_tissue_sarcoma,Head_and_neck_cancer,Breast_cancer_triple_negative,Hepatoblastoma"
"Cisplatin, Cetuximab, RT","Cisplatin, Cetuximab, RT",Adjuvant therapy,Head_and_neck_cancer
"Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine","Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine",Metastatic or unresectable disease,Melanoma
"Cisplatin, Dacarbazine, Paclitaxel","Cisplatin, Dacarbazine, Paclitaxel",Metastatic or unresectable disease,Melanoma
"Cisplatin, Docetaxel, RT","Cisplatin, Docetaxel, RT",Neoadjuvant chemoradiotherapy,"Esophageal_cancer,Non-small_cell_lung_cancer"
"Cisplatin, Doxorubicin liposomal, Fluorouracil","Cisplatin, Doxorubicin liposomal, Fluorouracil",Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
"Cisplatin, Doxorubicin, Paclitaxel","Cisplatin, Doxorubicin, Paclitaxel","Chemotherapy for advanced, recurrent, or metastatic disease",Endometrial_cancer
"Cisplatin, Doxorubicin, Paclitaxel",TAP,"Chemotherapy for advanced, recurrent, or metastatic disease",Endometrial_cancer
"Cisplatin, Epirubicin, Ifosfamide","Cisplatin, Epirubicin, Ifosfamide",Neoadjuvant therapy,Osteosarcoma
"Cisplatin, Etoposide, Bevacizumab","Cisplatin, Etoposide, Bevacizumab","Extensive stage, induction",Small_cell_lung_cancer
"Cisplatin, Etoposide, Irinotecan","Cisplatin, Etoposide, Irinotecan",Relapsed or refractory disease,Small_cell_lung_cancer
"Cisplatin, Etoposide, RT",EP  and  RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP+RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP / RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP/RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP & RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT","Cisplatin, Etoposide, RT",Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP + RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EP and RT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Etoposide, RT",EPRT,Definitive therapy for locally advanced disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer"
"Cisplatin, Fluorouracil, Cetuximab",CF/C,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Head_and_neck_cancer"
"Cisplatin, Fluorouracil, Cetuximab",CFC,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Head_and_neck_cancer"
"Cisplatin, Fluorouracil, Cetuximab",CF-C,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Head_and_neck_cancer"
"Cisplatin, Fluorouracil, Cetuximab","Cisplatin, Fluorouracil, Cetuximab",Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Head_and_neck_cancer"
"Cisplatin, Fluorouracil, Hydroxyurea, RT","Cisplatin, Fluorouracil, Hydroxyurea, RT",Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
"Cisplatin, Fluorouracil, Panitumumab","Cisplatin, Fluorouracil, Panitumumab","Recurrent or metastatic disease, first-line therapy",Head_and_neck_cancer
"Cisplatin, Fluorouracil, RT","Cisplatin, Fluorouracil, RT",Induction chemoradiotherapy,"Esophageal_cancer,Bladder_cancer,Head_and_neck_cancer,Cervical_cancer"
"Cisplatin, Gemcitabine, Bevacizumab","Cisplatin, Gemcitabine, Bevacizumab","Advanced or metastatic disease, first-line, nonsquamous",Non-small_cell_lung_cancer
"Cisplatin, Gemcitabine, Necitumumab","Cisplatin, Gemcitabine, Necitumumab","Advanced or metastatic disease, first-line, squamous",Non-small_cell_lung_cancer
"Cisplatin, Gemcitabine, RT","Cisplatin, Gemcitabine, RT",Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
"Cisplatin, Irinotecan, RT","Cisplatin, Irinotecan, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Cisplatin, Lomustine, Vincristine","Cisplatin, Lomustine, Vincristine",Adjuvant therapy,Medulloblastoma
"Cisplatin, Paclitaxel, Bevacizumab",CP / Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab","Cisplatin, Paclitaxel, Bevacizumab","Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CP&Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CP/Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CP & Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CP and Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CP+Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, Bevacizumab",CPBev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Cisplatin, Paclitaxel, RT","Cisplatin, Paclitaxel, RT",Induction chemoradiotherapy,"Esophageal_cancer,Bladder_cancer,Head_and_neck_cancer"
"Cisplatin, Pemetrexed, Bevacizumab",PCB,"Advanced or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Mesothelioma"
"Cisplatin, Pemetrexed, Bevacizumab","Cisplatin, Pemetrexed, Bevacizumab","Advanced or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Mesothelioma"
"Cisplatin, Vinblastine, RT","Cisplatin, Vinblastine, RT",Definitive therapy for locally advanced disease,Non-small_cell_lung_cancer
"Cisplatin, Vinorelbine, Cetuximab","Cisplatin, Vinorelbine, Cetuximab","Advanced or metastatic disease, first-line",Non-small_cell_lung_cancer
"Cisplatin, Vinorelbine, RT","Cisplatin, Vinorelbine, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
Cladribine & Cytarabine,Cladribine & Cytarabine,All lines of therapy,"Hypereosinophilic_syndrome,Langerhans_cell_histiocytosis"
Cladribine & Rituximab,Cladribine & Rituximab,Untreated,"Marginal_zone_lymphoma,Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma,Hairy_cell_leukemia"
Cladribine monotherapy,Cladribine monotherapy,"First-line therapy, randomized data","Chronic_lymphocytic_leukemia_(CLLSLL),Systemic_mastocytosis,Langerhans_cell_histiocytosis,Mantle_cell_lymphoma,Marginal_zone_lymphoma,Hairy_cell_leukemia"
Clofarabine & Cytarabine,Clofarabine & Cytarabine,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine + LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine / LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine/LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine+LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine & LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine  and  LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & LoDAC,Clofarabine and LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Clofarabine & Melphalan,Clofarabine & Melphalan,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Clofarabine monotherapy,Clofarabine monotherapy,"First-line induction therapy, older or ""unfit"" patients","Acute_myeloid_leukemia,Myelodysplastic_syndrome"
Cobimetinib & Vemurafenib,Cobimetinib & Vemurafenib,"Advanced or metastatic disease, BRAF inhibitor-naive",Melanoma_BRAF-mutated
Colchicine monotherapy,Colchicine monotherapy,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
Copanlisib monotherapy,Copanlisib monotherapy,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
Crizotinib monotherapy,Crizotinib monotherapy,"Advanced or metastatic disease, ALK inhibitor-naive","Non-small_cell_lung_cancer_ROS1-positive,Non-small_cell_lung_cancer_ALK-positive"
Cyclophosphamide & Dexamethasone,Cyclophosphamide & Dexamethasone,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Cyclophosphamide & Etoposide,Cyclophosphamide & Etoposide,"Relapsed, refractory, or metastatic, subsequent lines",Osteosarcoma
Cyclophosphamide & G-CSF,Cyclophosphamide & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cyclophosphamide & Prednisolone,Cyclophosphamide & Prednisolone,"Acquired hemophilia A, all lines of therapy",Acquired_coagulopathy
Cyclophosphamide & Prednisone,Cyclophosphamide & Prednisone,"Acquired hemophilia A, all lines of therapy","Multiple_myeloma_relapsedrefractory,Acquired_coagulopathy,Large_granular_lymphocytic_leukemia"
Cyclophosphamide & TBI,CyTBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Cyclophosphamide & TBI,Cyclophosphamide & TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Cyclophosphamide & TBI,Cy/TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Cyclophosphamide & Topotecan,Cyclophosphamide & Topotecan,Relapsed or refractory or metastatic,"Osteosarcoma,Ewings_sarcoma"
Cyclophosphamide & Vincristine,Cyclophosphamide & Vincristine,Relapsed or refractory,Neuroblastoma
Cyclophosphamide & Vincristine/Cisplatin & Etoposide,Cyclophosphamide & Vincristine/Cisplatin & Etoposide,Adjuvant therapy,Medulloblastoma
Cyclophosphamide monotherapy,Cyclophosphamide monotherapy,"Recurrent disease, salvage therapy","Neuroblastoma,Follicular_lymphoma,Glioblastoma,Anaplastic_glioma,Large_granular_lymphocytic_leukemia"
"Cyclophosphamide, Dacarbazine, Vincristine","Cyclophosphamide, Dacarbazine, Vincristine",All lines of therapy,Pheochromocytoma
"Cyclophosphamide, Dacarbazine, Vincristine",CVD,All lines of therapy,Pheochromocytoma
"Cyclophosphamide, Etoposide, TBI","Cyclophosphamide, Etoposide, TBI","High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"Cyclophosphamide, Fludarabine, Thiotepa","Cyclophosphamide, Fludarabine, Thiotepa","Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Cyclosporine & Prednisone,Cyclosporine & Prednisone,"Treatment, cGVHD, all lines of therapy",Graft_versus_host_disease_(GVHD)
Cyclosporine monotherapy,Cyclosporine monotherapy,Initial therapy,"Myelodysplastic_syndrome,Aplastic_anemia,Immune_thrombocytopenia_(ITP),Castleman_disease"
"Cyclosporine, Corticosteroids, Rituximab","Cyclosporine, Corticosteroids, Rituximab","Treatment, cGVHD, all lines of therapy",Graft_versus_host_disease_(GVHD)
"Cyclosporine, Methotrexate, MP","Cyclosporine, Methotrexate, MP",Prevention,Graft_versus_host_disease_(GVHD)
"Cyclosporine, Methotrexate, Prednisone","Cyclosporine, Methotrexate, Prednisone",Prevention,Graft_versus_host_disease_(GVHD)
"Cyclosporine, Sirolimus, Prednisone","Cyclosporine, Sirolimus, Prednisone","Treatment, cGVHD, all lines of therapy",Graft_versus_host_disease_(GVHD)
Cytarabine & Daunorubicin,Cytarabine & Daunorubicin,Consolidation after upfront therapy,"Acute_myeloid_leukemia,Acute_promyelocytic_leukemia"
Cytarabine & G-CSF,Cytarabine  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & G-CSF,Cytarabine/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Cytarabine & Idarubicin,Cytarabine & Idarubicin,Consolidation after upfront therapy,"Acute_myeloid_leukemia,Acute_promyelocytic_leukemia"
"Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine","Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine",Consolidation after upfront therapy,Acute_promyelocytic_leukemia
"Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA","Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA",Consolidation after upfront therapy,Acute_promyelocytic_leukemia
Cytarabine & Mitoxantrone,MIDAC,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
Cytarabine & Mitoxantrone,Cytarabine & Mitoxantrone,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
Cytarabine & Thioguanine,Cytarabine & Thioguanine,Consolidation after salvage therapy,Acute_myeloid_leukemia
"Cytarabine, Daunorubicin, Gemtuzumab ozogamicin","Cytarabine, Daunorubicin, Gemtuzumab ozogamicin",Consolidation after upfront therapy,Acute_myeloid_leukemia
"Cytarabine, Idarubicin, Imatinib","Cytarabine, Idarubicin, Imatinib",Late intensification,B-cell_acute_lymphoblastic_leukemia_Ph-positive
"Cytarabine, Idarubicin, Sorafenib","Cytarabine, Idarubicin, Sorafenib",Consolidation after upfront therapy,Acute_myeloid_leukemia
"Cytarabine, Ifosfamide, G-CSF","Cytarabine, Ifosfamide, G-CSF","Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
"Cytarabine, Methotrexate, Rituximab","Cytarabine, Methotrexate, Rituximab","Upfront therapy, randomized data",CNS_lymphoma
D-VMP,D/VMP,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
D-VMP,D-VMP,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
D-VMP,DVMP,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
DA 3 + 10,DA 3  &  10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA310,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3  /  10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3 + 10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3 / 10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3 & 10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3  10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA 3 + 10,DA 3  and  10,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
"DA 3 + 10, GO","DA 3 + 10, GO","Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DA-EPOCH,DA/EPOCH,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
DA-EPOCH,DAEPOCH,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
DA-EPOCH,DA-EPOCH,Untreated,"Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
DA-R-EPOCH,DA-R-EPOCH,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mediastinal_gray-zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
DA-R-EPOCH,DAREPOCH,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mediastinal_gray-zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
DA-R-EPOCH,DA/R/EPOCH,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mediastinal_gray-zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
DAC,DAC,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
DCEP,DCEP,Consolidation after first-line therapy,"Multiple_myeloma_relapsedrefractory,Multiple_myeloma_consolidation_and_maintenance"
DCEP & G-CSF,DCEP / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCEP & G-CSF,DCEP & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DCF,TCF,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Penile_cancer,SCC_of_unknown_primary,Nasopharyngeal_carcinoma,Esophageal_cancer,Head_and_neck_cancer"
DCF,DCF,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Penile_cancer,SCC_of_unknown_primary,Nasopharyngeal_carcinoma,Esophageal_cancer,Head_and_neck_cancer"
DD-CHOP,DDCHOP,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
DD-CHOP,DD-CHOP,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
DD-CHOP,DD/CHOP,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
DDGP,DDGP,All lines of therapy,NKT-cell_lymphoma
DE,DE,Neoadjuvant chemotherapy,Breast_cancer
DEB-TACE,DEBTACE,Local therapy,Hepatocellular_carcinoma
DEB-TACE,DEB-TACE,Local therapy,Hepatocellular_carcinoma
DEB-TACE,DEB/TACE,Local therapy,Hepatocellular_carcinoma
DEP & RT,DEP & RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP + RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP / RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP  and  RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEPRT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP/RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP and RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DEP & RT,DEP+RT,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
DHAP,DHAP,"Relapsed or refractory, salvage therapy","Hodgkin_lymphoma,Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
DHAP - time intensified,DHAP - time intensified,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
DI EC,DI EC,Neoadjuvant chemotherapy,Breast_cancer
DI EC,DIEC,Neoadjuvant chemotherapy,Breast_cancer
DOF,DOF,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
DRC,DRC,"First-line therapy, non-randomized or retrospective data",Waldenstrom_macroglobulinemia
DRd,DRd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
DTPACE,DTPACE,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
DVd,DVd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Dabigatran monotherapy,Dabigatran monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Dabrafenib & Trametinib,Dabrafenib & Trametinib,All lines of therapy,"Melanoma_BRAF-mutated,CNS_melanoma,Thyroid_cancer_BRAF-mutated,Non-small_cell_lung_cancer_BRAF-mutated,BRAF"
Dabrafenib monotherapy,Dabrafenib monotherapy,All lines of therapy,"Melanoma_BRAF-mutated,CNS_melanoma"
Dacarbazine & Doxorubicin,Dacarbazine & Doxorubicin,"Locally advanced or metastatic disease, combination regimens",Soft_tissue_sarcoma
Dacarbazine & Gemcitabine,Dacarbazine & Gemcitabine,"Leiomyosarcoma (LMS), all lines of therapy",Soft_tissue_sarcoma
Dacarbazine & Interferon alfa,Dacarbazine & Interferon alfa,Metastatic or unresectable disease,Melanoma
Dacarbazine & Ipilimumab,Dacarbazine & Ipilimumab,Metastatic or unresectable disease,Melanoma
Dacarbazine monotherapy,Dacarbazine monotherapy,Metastatic or unresectable disease,"Soft_tissue_sarcoma,Melanoma"
Dacomitinib monotherapy,Dacomitinib monotherapy,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Dactinomycin & Vincristine,Dactinomycin & Vincristine,All lines of therapy,Wilms_tumor
Dactinomycin monotherapy,Dactinomycin monotherapy,"Chemotherapy for advanced, recurrent, or metastatic disease","Endometrial_cancer,Gestational_trophoblastic_neoplasia,Wilms_tumor"
Dalteparin monotherapy,Dalteparin monotherapy,VTE secondary prevention,Venous_thromboembolism_(VTE)
Danaparoid monotherapy,Danaparoid monotherapy,All lines of therapy,Heparin-induced_thrombocytopenia_(HIT)
Daratumumab monotherapy,Daratumumab monotherapy,Relapsed or refractory,"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
Dasatinib & Prednisone,Dasatinib & Prednisone,Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Dasatinib monotherapy,Dasatinib monotherapy,Maintenance after upfront therapy,"Systemic_mastocytosis,Chronic_myelogenous_leukemia,B-cell_acute_lymphoblastic_leukemia_Ph-positive"
"Dasatinib, Vincristine, Prednisone","Dasatinib, Vincristine, Prednisone",Maintenance after upfront therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Daunorubicin liposomal monotherapy,Daunorubicin liposomal monotherapy,"Kaposi sarcoma, all lines of therapy",Vascular_sarcoma
Daunorubicin monotherapy,Daunorubicin monotherapy,Consolidation after upfront therapy,Acute_promyelocytic_leukemia
"Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib","Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib",Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
"Daunorubicin, Vincristine, Prednisolone, Nilotinib","Daunorubicin, Vincristine, Prednisolone, Nilotinib",Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Decitabine monotherapy,Decitabine monotherapy,"First-line induction therapy, older or ""unfit"" patients","Chronic_myelomonocytic_leukemia,Acute_myeloid_leukemia,Myelodysplastic_syndrome"
Denileukin diftitox monotherapy,Denileukin diftitox monotherapy,Relapsed or refractory,Cutaneous_T-cell_lymphoma
Denosumab monotherapy,Denosumab monotherapy,"Giant-cell tumor of bone, all lines of therapy",Bone_sarcoma
DexaBEAM,DexaBEAM,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
DexaBEAM & G-CSF,DexaBEAM / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
DexaBEAM & G-CSF,DexaBEAM+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
Dexamethasone & Eltrombopag,Dexamethasone & Eltrombopag,Initial therapy,Immune_thrombocytopenia_(ITP)
Dexamethasone & Rituximab,Dexamethasone & Rituximab,Initial therapy,Immune_thrombocytopenia_(ITP)
Dexamethasone & WBRT,Dexamethasone & WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone / WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone and WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone+WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone/WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone  and  WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone & WBRT,Dexamethasone + WBRT,"Non-small cell lung cancer, all lines of therapy",CNS_carcinoma
Dexamethasone monotherapy,Dexamethasone monotherapy,"Non-small cell lung cancer, all lines of therapy","Immune_thrombocytopenia_(ITP),CNS_carcinoma"
"Dinutuximab, GM-CSF, IL-2, Isotretinoin","Dinutuximab, GM-CSF, IL-2, Isotretinoin","High-risk, consolidation",Neuroblastoma
Docetaxel & Bevacizumab,Docetaxel & Bevacizumab,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev+D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T and Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev & D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev/D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev and D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T+Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,TBev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,BevD,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev / D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T & Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T/Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,Bev&D,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T / Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Bevacizumab,T&Bev,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
Docetaxel & Gemcitabine,Docetaxel & Gemcitabine,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Osteosarcoma,Soft_tissue_sarcoma,Ewings_sarcoma"
Docetaxel & Irinotecan,Docetaxel & Irinotecan,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
Docetaxel & Ramucirumab,Docetaxel & Ramucirumab,"Locally advanced or metastatic disease, subsequent lines","Non-small_cell_lung_cancer,Bladder_cancer"
Docetaxel & Vandetanib,Docetaxel & Vandetanib,"Advanced or metastatic disease, subsequent lines of therapy",Non-small_cell_lung_cancer
Docetaxel monotherapy,Docetaxel monotherapy,"Locally advanced or metastatic disease, subsequent lines","Non-small_cell_lung_cancer,Gastric_cancer,Ovarian_cancer,Bladder_cancer,Cervical_cancer,Esophageal_cancer,Breast_cancer,Small_cell_lung_cancer,Head_and_neck_cancer,Melanoma"
"Docetaxel, Cetuximab, RT","Docetaxel, Cetuximab, RT",Adjuvant therapy,Head_and_neck_cancer
"Docetaxel, Fluorouracil, Hydroxyurea, RT","Docetaxel, Fluorouracil, Hydroxyurea, RT","Locally advanced disease, definitive therapy",Head_and_neck_cancer
"Docetaxel, Fluorouracil, RT","Docetaxel, Fluorouracil, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Docetaxel, Gemcitabine, RT","Docetaxel, Gemcitabine, RT","Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Doxorubicin & Gemcitabine,Doxorubicin & Gemcitabine,"Metastatic disease, first-line",Renal_cell_carcinoma
Doxorubicin & Ifosfamide,Doxorubicin & Ifosfamide,"Locally advanced or metastatic disease, combination regimens",Soft_tissue_sarcoma
Doxorubicin & Ifosfamide,AIM,"Locally advanced or metastatic disease, combination regimens",Soft_tissue_sarcoma
Doxorubicin & Olaratumab,Doxorubicin & Olaratumab,"Locally advanced or metastatic disease, combination regimens",Soft_tissue_sarcoma
Doxorubicin & Streptozocin,Doxorubicin & Streptozocin,All lines of therapy,Pancreatic_NET
Doxorubicin monotherapy,Doxorubicin monotherapy,"Chemotherapy for advanced, recurrent, or metastatic disease","Hepatocellular_carcinoma,Osteosarcoma,Mesothelioma,Soft_tissue_sarcoma,Thyroid_cancer,Endometrial_cancer"
Doxorubicin pegylated liposomal & Bevacizumab,Doxorubicin pegylated liposomal & Bevacizumab,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Doxorubicin pegylated liposomal & Gemcitabine,Doxorubicin pegylated liposomal & Gemcitabine,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Doxorubicin pegylated liposomal & Trabectedin,Doxorubicin pegylated liposomal & Trabectedin,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Doxorubicin pegylated liposomal monotherapy,Doxorubicin pegylated liposomal monotherapy,"Relapsed or recurrent disease, platinum-resistant","Ovarian_cancer,Vascular_sarcoma"
Durvalumab monotherapy,Durvalumab monotherapy,Consolidation or maintenance after definitive therapy for inoperable disease,Non-small_cell_lung_cancer
Duvelisib monotherapy,Duvelisib monotherapy,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
EAR & G-CSF,EAR and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EAR & G-CSF,EAR+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
EBVP,EBVP,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
EBd,EBd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
EC,EC,Neoadjuvant chemotherapy,Breast_cancer
EC & Bevacizumab,EC+Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC/Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC / Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC + Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC and Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC & Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
EC & Bevacizumab,EC  and  Bevacizumab,Neoadjuvant chemotherapy,Breast_cancer_triple_negative
ECF,ECF,"Metastatic disease, all lines of therapy","Cholangiocarcinoma,Esophageal_cancer,Gastric_cancer"
"ECF, then 5-FU & RT, then ECF","ECF, then 5-FU & RT, then ECF",Adjuvant therapy,Esophageal_cancer
ECH,ECH,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
ECX,ECX,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
EIA,EIA,Neoadjuvant therapy,Soft_tissue_sarcoma
ELd,ERd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
ELd,ELd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
EOF,EOF,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
EOX,EOC,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
EOX,EOX,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
EP,EP,Neoadjuvant chemotherapy,Breast_cancer
"EPOCH, dose-escalated","EPOCH, dose-escalated",Upfront therapy,HIV-associated_lymphoma
"EPOCH, dose-escalated",EPOCH,Upfront therapy,HIV-associated_lymphoma
ESHAP,ESHAP,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
EVAIA,EVAIA,Neoadjuvant therapy,Ewings_sarcoma
Eculizumab monotherapy,Eculizumab monotherapy,All lines of therapy,"Atypical_hemolytic-uremic_syndrome_(aHUS),Paroxysmal_nocturnal_hemoglobinuria_(PNH),Cold_agglutinin_disease"
Edoxaban monotherapy,Edoxaban monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Elo-Pom-dex,Elo-Pom-dex,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Emicizumab monotherapy,Emicizumab monotherapy,"Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy",Inherited_coagulopathy
Enasidenib monotherapy,Enasidenib monotherapy,"IDH2 Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia_IDH-mutated
Enoxaparin monotherapy,Enoxaparin monotherapy,VTE primary prophylaxis,Venous_thromboembolism_(VTE)
Epirubicin & Ifosfamide,Epirubicin & Ifosfamide,Relapsed or refractory disease,"Soft_tissue_sarcoma,Small_cell_lung_cancer"
Epirubicin monotherapy,Epirubicin monotherapy,"Locally advanced or metastatic disease, single-agent regimens",Soft_tissue_sarcoma
Epoetin & Lenalidomide,Epoetin & Lenalidomide,First-line therapy,Myelodysplastic_syndrome
Eribulin monotherapy,Eribulin monotherapy,"Leiomyosarcoma (LMS), all lines of therapy",Soft_tissue_sarcoma
Erlotinib & Bevacizumab,Erlotinib & Bevacizumab,All lines of therapy,"Adenocarcinoma_of_unknown_primary,Hepatocellular_carcinoma,Renal_cell_carcinoma,Cholangiocarcinoma,Non-small_cell_lung_cancer_EGFR-mutated"
Erlotinib & Gemcitabine,Erlotinib & Gemcitabine,"Induction therapy for locally advanced disease, unresectable",Pancreatic_cancer
Erlotinib monotherapy,Erlotinib monotherapy,All lines of therapy,"Myelodysplastic_syndrome,Renal_cell_carcinoma,EGFR,Esophageal_cancer,Non-small_cell_lung_cancer_EGFR-mutated"
Etoposide & Mitoxantrone,Etoposide & Mitoxantrone,Consolidation after upfront therapy,Acute_myeloid_leukemia
Etoposide & Prednisone,Etoposide & Prednisone,Untreated,Langerhans_cell_histiocytosis
Etoposide & TBI,Etoposide  and  TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide / TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide+TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide and TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide + TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide/TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide & TBI,Etoposide & TBI,"Myeloablative regimens, all lines of therapy","Autologous_HSCT,Allogeneic_HSCT"
Etoposide monotherapy,Etoposide monotherapy,"Recurrent disease, salvage therapy","Diffuse_large_B-cell_lymphoma,Ovarian_cancer,Esophageal_cancer,Testicular_cancer,Anaplastic_glioma,Small_cell_lung_cancer,Vascular_sarcoma"
Everolimus & Lenvatinib,Everolimus & Lenvatinib,"Metastatic disease, second-line",Renal_cell_carcinoma
Everolimus & Rituximab,Everolimus & Rituximab,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
Everolimus monotherapy,Everolimus monotherapy,"Relapsed or refractory, further lines of therapy","Waldenstrom_macroglobulinemia,Diffuse_large_B-cell_lymphoma,Pancreatic_NET,Renal_cell_carcinoma,Hodgkin_lymphoma,Mantle_cell_lymphoma,Neuroendocrine_tumors,Thymoma"
F-SHAI,F/SHAI,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
F-SHAI,FSHAI,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
F-SHAI,F-SHAI,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
FAC,FAC,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
FAS,FAS,All lines of therapy,Pancreatic_NET
FC,FC,"Reduced-intensity conditioning (RIC), all lines of therapy","Mantle_cell_lymphoma,Autologous_HSCT,Allogeneic_HSCT"
FCA,FCCam,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
FCA,FCA,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
FCM,FCM,"First-line therapy, randomized data","Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
FCR,FCR,"Reduced-intensity conditioning (RIC), all lines of therapy","Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Allogeneic_HSCT"
FEAM,FEAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
FEC,FEC,Neoadjuvant chemotherapy,Breast_cancer
FEC & H,FEC  and  H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC and H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC/H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC + H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC / H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC & H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FEC+H,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FEC & H,FECH,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
FELV,FELV,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
FLAG,FLAG,"Relapsed or refractory, salvage therapy",Acute_myeloid_leukemia
FLAG-Ida,FLAG-Ida,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
FLAG-Ida,FLAGIda,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
FLAG-Ida,FLAG/Ida,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
FLEP,FLEP,Neoadjuvant induction therapy,Esophageal_cancer
FLOT,FLOT,Neoadjuvant induction therapy,"Esophageal_cancer,Gastric_cancer"
FLOX,FLOX,Adjuvant therapy,Colon_cancer
FOLFIRI,FOLFIRI,"Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy","Esophageal_cancer,Pancreatic_cancer,Colon_cancer"
FOLFIRI & Bevacizumab,FOLFIRI & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFIRI & Cetuximab,FOLFIRI/Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI + Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI and Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI / Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI & Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI  and  Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Cetuximab,FOLFIRI+Cetuximab,Perioperative therapy for oligometastatic disease,Colon_cancer_KRAS_wild-type
FOLFIRI & Panitumumab,FOLFIRI & Panitumumab,"Advanced or metastatic disease, second-line",Colon_cancer_KRAS_wild-type
FOLFIRI & Ramucirumab,FOLFIRI & Ramucirumab,"Advanced or metastatic disease, second-line therapy",Colon_cancer
FOLFIRI & Ziv-aflibercept,FOLFIRI & Ziv-aflibercept,"Advanced or metastatic disease, second-line therapy",Colon_cancer
FOLFIRINOX,FOLFOXIRI,"Advanced or metastatic disease, first-line","Pancreatic_cancer,Colon_cancer"
FOLFIRINOX,FOLFIRINOX,"Advanced or metastatic disease, first-line","Pancreatic_cancer,Colon_cancer"
FOLFIRINOX & Bevacizumab,FOLFIRINOX & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFIRINOX & Bevacizumab,FOLFOXIRI & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX,FOLFOX,"Metastatic disease, refractory","Pancreatic_cancer,Rectal_cancer"
FOLFOX2,FOLFOX2,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX4,FOLFOX4,Adjuvant therapy,"Esophageal_cancer,Hepatocellular_carcinoma,Colon_cancer"
FOLFOX4 & Bevacizumab,FOLFOX/B,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX4 & Bevacizumab,FOLFOX4 & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX4 & Bevacizumab,FOLFOX-B,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX4 & Bevacizumab,FOLFOXB,"Advanced or metastatic disease, first-line",Colon_cancer
FOLFOX4 & Cetuximab,FOLFOX4 / Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4 & Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4  and  Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4+Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4 and Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4 + Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Cetuximab,FOLFOX4/Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & Panitumumab,FOLFOX4 & Panitumumab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
FOLFOX4 & RT,FOLFOX4+RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4 / RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4  and  RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4 & RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4 and RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4/RT,Definitive therapy,Esophageal_cancer
FOLFOX4 & RT,FOLFOX4 + RT,Definitive therapy,Esophageal_cancer
"FP, then Capecitabine & RT, then FP","FP, then Capecitabine & RT, then FP",Adjuvant therapy,Gastric_cancer
FR,FR,All lines of therapy,"Waldenstrom_macroglobulinemia,Follicular_lymphoma,Mantle_cell_lymphoma,Cold_agglutinin_disease,Marginal_zone_lymphoma"
FRD,FRD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
FluCam,FluCam,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Fludarabine & Alemtuzumab,Fludarabine & Alemtuzumab,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Fludarabine & Melphalan,Fludarabine & Melphalan,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & Melphalan,Flu/Mel,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & Melphalan,FluMel,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & Melphalan,Flu-Mel,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & Prednisone,Fludarabine & Prednisone,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Fludarabine & TBI,Fludarabine and TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine/TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine / TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine+TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine & TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine  and  TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine & TBI,Fludarabine + TBI,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fludarabine monotherapy,Fludarabine monotherapy,"Relapsed or refractory, randomized data","Waldenstrom_macroglobulinemia,Marginal_zone_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
"Fludarabine, Busulfan, ATG","Fludarabine, Busulfan, ATG","Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
"Fludarabine, Busulfan, Cyclophosphamide","Fludarabine, Busulfan, Cyclophosphamide","Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
"Fludarabine, Busulfan, Cyclophosphamide",FluBuCy,"Myeloablative regimens, all lines of therapy",Allogeneic_HSCT
"Fludarabine, Cyclophosphamide, ATG","Fludarabine, Cyclophosphamide, ATG","Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
"Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant",dUCB,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
"Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant","Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant","Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
"Fludarabine, Melphalan, Alemtuzumab","Fludarabine, Melphalan, Alemtuzumab","Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
Fluorouracil & Folinic acid,Fluorouracil & Folinic acid,"Advanced or metastatic disease, subsequent lines of therapy","Hepatocellular_carcinoma,Colon_cancer,Cervical_cancer,Cholangiocarcinoma,Esophageal_cancer,Rectal_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil and RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil / RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil & RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil  and  RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil+RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil + RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & RT,Fluorouracil/RT,Definitive chemoradiotherapy for locally advanced disease,"Head_and_neck_cancer,Rectal_cancer,Cervical_cancer,Pancreatic_cancer"
Fluorouracil & Streptozocin,Fluorouracil & Streptozocin,All lines of therapy,"Pancreatic_NET,Neuroendocrine_tumors"
Fluorouracil monotherapy,Fluorouracil monotherapy,"Advanced or metastatic disease, first-line","Colon_cancer,Gastric_cancer,Rectal_cancer,Head_and_neck_cancer,Pancreatic_cancer"
"Fluorouracil, Folinic acid, Gemcitabine","Fluorouracil, Folinic acid, Gemcitabine","Metastatic disease, all lines of therapy","Cholangiocarcinoma,Esophageal_cancer"
"Fluorouracil, Folinic acid, Mitomycin","Fluorouracil, Folinic acid, Mitomycin","Metastatic or locally advanced disease, first-line",Gastric_cancer
"Fluorouracil, Folinic acid, RT","Fluorouracil, Folinic acid, RT",Neoadjuvant therapy,Rectal_cancer
"Fluorouracil, Folinic acid, nanoliposomal Irinotecan","Fluorouracil, Folinic acid, nanoliposomal Irinotecan","Metastatic disease, refractory",Pancreatic_cancer
"Fluorouracil, Hydroxyurea, RT","Fluorouracil, Hydroxyurea, RT","Locally advanced disease, definitive therapy",Head_and_neck_cancer
"Fluorouracil, Mitomycin, RT","Fluorouracil, Mitomycin, RT",Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer,Cervical_cancer"
"Fluorouracil, Oxaliplatin, RT","Fluorouracil, Oxaliplatin, RT",Neoadjuvant chemoradiotherapy,"Esophageal_cancer,Rectal_cancer"
"Fluorouracil, Paclitaxel, RT","Fluorouracil, Paclitaxel, RT",Neoadjuvant chemoradiotherapy,Esophageal_cancer
"Fluorouracil, then Fluorouracil & RT, then Fluorouracil","Fluorouracil, then Fluorouracil & RT, then Fluorouracil",Adjuvant chemoradiotherapy,Rectal_cancer
Fluorouracil/Fluorouracil & RT,Fluorouracil/Fluorouracil & RT,Adjuvant therapy,Pancreatic_cancer
Fondaparinux monotherapy,Fondaparinux monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Fondaprinux monotherapy,Fondaprinux monotherapy,All lines of therapy,Heparin-induced_thrombocytopenia_(HIT)
Forodesine monotherapy,Forodesine monotherapy,"Relapsed or refractory, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
Fostamatinib monotherapy,Fostamatinib monotherapy,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
Fotemustine monotherapy,Fotemustine monotherapy,Metastatic or unresectable disease,Melanoma
G-CHOP,GCHOP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-CHOP,G-CHOP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-CHOP,G/CHOP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-CVP,G-CVP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-CVP,G/CVP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-CVP,GCVP,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
G-FC,GFC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
G-FC,G/FC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
G-FC,G-FC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
GCD,GCD,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
GCD-R,GCDR,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
GCD-R,GCD-R,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
GCD-R,GCD/R,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
GCP,GCP,All lines of therapy,Adenocarcinoma_of_unknown_primary
GDP,GDP,"Relapsed or refractory, salvage therapy","Peripheral_T-cell_lymphoma,Anaplastic_large_cell_lymphoma"
GDPT,GDPT,"Untreated, randomized data",Peripheral_T-cell_lymphoma
"GELOX, then RT","GELOX, then RT",Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
GEMOX-B,GEMOX/B,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
GEMOX-B,GEMOX-B,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
GEMOX-B,GEMOXB,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
GIP,GIP,"Relapsed or refractory, salvage therapy",Testicular_cancer
GTX,GTX,"Metastatic disease, first-line",Pancreatic_cancer
GVD,GVD,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Hodgkin_lymphoma"
GVP,GVP,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Gefitinib & Pemetrexed,P&G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,P / G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,P+G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,Gefitinib & Pemetrexed,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,P/G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,P & G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib & Pemetrexed,P and G,"Advanced or metastatic disease, EGFR inhibitor-naive",Non-small_cell_lung_cancer_EGFR-mutated
Gefitinib monotherapy,Gefitinib monotherapy,"Advanced or metastatic disease, first-line, nonsquamous","Non-small_cell_lung_cancer,Non-small_cell_lung_cancer_EGFR-mutated"
GemOx,GemOx,First-line therapy for advanced or metastatic disease,"Testicular_cancer,Hepatocellular_carcinoma,Pancreatic_cancer"
Gemcitabine & Irinotecan,Gemcitabine & Irinotecan,All lines of therapy,Adenocarcinoma_of_unknown_primary
Gemcitabine & Mitomycin,Gemcitabine & Mitomycin,"Metastatic disease, all lines of therapy",Cholangiocarcinoma
Gemcitabine & Paclitaxel,Gemcitabine & Paclitaxel,"Locally advanced or metastatic disease, first-line","Non-small_cell_lung_cancer,Testicular_cancer,Bladder_cancer"
Gemcitabine & RT,Gemcitabine & RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine  and  RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine + RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine+RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine / RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine and RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & RT,Gemcitabine/RT,"Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
Gemcitabine & Rituximab,Gemcitabine & Rituximab,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Gemcitabine & Sunitinib,Gemcitabine & Sunitinib,"Metastatic disease, first-line",Renal_cell_carcinoma
Gemcitabine & Vinorelbine,Gemcitabine & Vinorelbine,"Advanced or metastatic disease, subsequent lines of therapy","Non-small_cell_lung_cancer,Soft_tissue_sarcoma,Mesothelioma"
Gemcitabine & nab-Paclitaxel,Gemcitabine & nab-Paclitaxel,"Metastatic disease, all lines of therapy","Cholangiocarcinoma,Pancreatic_cancer"
Gemcitabine monotherapy,Gemcitabine monotherapy,Intravesical chemotherapy,"Non-small_cell_lung_cancer,Diffuse_large_B-cell_lymphoma,Ovarian_cancer,Osteosarcoma,Bladder_cancer,Cervical_cancer,Mesothelioma,Cholangiocarcinoma,Hodgkin_lymphoma,Small_cell_lung_cancer,Pancreatic_cancer"
"Gemcitabine, Cetuximab, RT","Gemcitabine, Cetuximab, RT","Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
"Gemcitabine, Oxaliplatin, Paclitaxel",GOP,Subsequent lines of therapy,Testicular_cancer
"Gemcitabine, Oxaliplatin, Paclitaxel","Gemcitabine, Oxaliplatin, Paclitaxel",Subsequent lines of therapy,Testicular_cancer
"Gemcitabine, then Fluorouracil & RT, then Gemcitabine","Gemcitabine, then Fluorouracil & RT, then Gemcitabine",Adjuvant therapy,Cholangiocarcinoma
Gemcitabine/Fluorouracil & RT,Gemcitabine/Fluorouracil & RT,Adjuvant therapy,Pancreatic_cancer
Gemtuzumab ozogamicin monotherapy,Gemtuzumab ozogamicin monotherapy,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Gilteritinib monotherapy,Gilteritinib monotherapy,"Relapsed or refractory, further lines of therapy",Acute_myeloid_leukemia_FLT3-positive
Glasdegib & LoDAC,Glasdegib  and  LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib + LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib & LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib+LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib / LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib/LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Glasdegib & LoDAC,Glasdegib and LoDAC,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Gliadel wafer,Gliadel wafer,"Recurrent disease, non-curative therapy, randomized data",Glioblastoma
HAA,HAA,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
HAD,HAD,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
HAM,HAM,Consolidation after upfront therapy,Acute_myeloid_leukemia
HAM & Imatinib,HAM  and  Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM / Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM + Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM/Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM and Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM & Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HAM & Imatinib,HAM+Imatinib,Consolidation after upfront therapy (including post-remission therapy),B-cell_acute_lymphoblastic_leukemia_Ph-positive
HDAC & G-CSF,HDAC/G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC and G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC / G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC + G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC  and  G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC & G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDAC & G-CSF,HDAC+G-CSF,Consolidation after upfront therapy,Acute_myeloid_leukemia
HDMP-R,HDMP-R,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
HDMP-R,HDMPR,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
HDMP-R,HDMP/R,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Heparin monotherapy,Heparin monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Hepatic arterial chemotherapy,Hepatic arterial chemotherapy,"Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",Colon_cancer
HiDAC,HDAraC,Consolidation after upfront therapy,"CNS_lymphoma,Acute_myeloid_leukemia"
HiDAC,HDAC,Consolidation after upfront therapy,"CNS_lymphoma,Acute_myeloid_leukemia"
HiDAC,HiDAC,Consolidation after upfront therapy,"CNS_lymphoma,Acute_myeloid_leukemia"
High-dose Interleukin-2,HDIL2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
High-dose Interleukin-2,HD IL2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
High-dose Interleukin-2,HD IL/2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
High-dose Interleukin-2,HD IL-2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
High-dose Interleukin-2,High-dose Interleukin-2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Hydroxyurea & Imatinib,Hydroxyurea & Imatinib,"Recurrent disease, non-curative therapy, randomized data",Glioblastoma
Hydroxyurea & RT,Hydroxyurea / RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea  and  RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea & RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea+RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea/RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea + RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea & RT,Hydroxyurea and RT,Definitive chemoradiotherapy for locally advanced disease,Cervical_cancer
Hydroxyurea monotherapy,Hydroxyurea monotherapy,First-line therapy,"Glioblastoma,Sickle_cell_anemia,Hypereosinophilic_syndrome,Polycythemia_vera,Essential_thrombocythemia"
Hyper-CVAD,HyperCVAD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Hyper-CVAD,Hyper-CVAD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Hyper-CVAD,Hyper/CVAD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Hyper-CVAD & Dasatinib,Hyper-CVAD & Dasatinib,Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Hyper-CVAD & Imatinib,Hyper-CVAD & Imatinib,Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
HyperCHidam,HyperCHidam,"Untreated, non-randomized or retrospective data",Peripheral_T-cell_lymphoma
ICE,ICE,Relapsed or refractory or metastatic,"Hodgkin_lymphoma,Osteosarcoma,Ewings_sarcoma"
ICL,ICL,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
IDAC,mIDAC,Consolidation after upfront therapy,Acute_myeloid_leukemia
IDAC,IDAC,Consolidation after upfront therapy,Acute_myeloid_leukemia
IDAC & Sorafenib,IDAC+Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC  and  Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC & Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC / Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC + Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC/Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IDAC & Sorafenib,IDAC and Sorafenib,Consolidation after upfront therapy,Acute_myeloid_leukemia_FLT3-positive
IE,IE,Relapsed or refractory or metastatic,"Osteosarcoma,Ewings_sarcoma"
IFL,mIFL,"Advanced or metastatic disease, first-line",Colon_cancer
IFL,IFL,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL/Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL+Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL  and  Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL + Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL and Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL  and  Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL / Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL + Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL / Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,IFL+Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL and Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IFL & Bevacizumab,mIFL/Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IGEV,IGEV,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
IGEV & G-CSF,IGEV + G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV and G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV / G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV+G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV/G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV & G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IGEV & G-CSF,IGEV  and  G-CSF,"Stem cell mobilization, all lines of therapy",Stem_cell_mobilization
IP-BCD,IPBCD,Adjuvant therapy,Osteosarcoma
IP-BCD,IP/BCD,Adjuvant therapy,Osteosarcoma
IP-BCD,IP-BCD,Adjuvant therapy,Osteosarcoma
IRIS,IRIS,"Advanced or metastatic disease, second-line therapy",Colon_cancer
IRIS & Bevacizumab,IRIS / Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS/Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS  and  Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS + Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS+Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IRIS & Bevacizumab,IRIS and Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
IROX,IROX,"Advanced or metastatic disease, first-line",Colon_cancer
IRd,IRd,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
IT Cytarabine & WBRT,Cytarabine and WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine/WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine / WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine + WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine + WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine+WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine and WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine  and  WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine & WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine+WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine  and  WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine & WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,IT Cytarabine / WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine & WBRT,Cytarabine/WBRT,CNS prophylaxis,CNS_leukemia
IT Cytarabine liposomal monotherapy,IT Cytarabine liposomal monotherapy,"Intrathecal, treatment",CNS_lymphoma
IT Cytarabine monotherapy,IT Cytarabine monotherapy,"Intrathecal, treatment",CNS_lymphoma
"IT Cytarabine, Methotrexate, WBRT","Cytarabine, Methotrexate, WBRT",CNS treatment,CNS_leukemia
"IT Cytarabine, Methotrexate, WBRT","IT Cytarabine, Methotrexate, WBRT",CNS treatment,CNS_leukemia
IT Methotrexate & WBRT,IT Methotrexate & WBRT,CNS prophylaxis,CNS_leukemia
IT Methotrexate monotherapy,IT Methotrexate monotherapy,CNS treatment,CNS_leukemia
Ibritumomab tiuxetan monotherapy,Ibritumomab tiuxetan monotherapy,"Early disease, definitive therapy","Marginal_zone_lymphoma,Mantle_cell_lymphoma,Follicular_lymphoma"
Ibrutinib & Obinutuzumab,Ibrutinib & Obinutuzumab,"First-line therapy, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Ibrutinib & Ofatumumab,Ibrutinib & Ofatumumab,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Ibrutinib & Rituximab,Ibrutinib & Rituximab,"Relapsed or refractory, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
Ibrutinib & Venetoclax,Ibrutinib & Venetoclax,"Relapsed or refractory, non-randomized or retrospective data",Mantle_cell_lymphoma
Ibrutinib monotherapy,Ibrutinib monotherapy,"First-line therapy, randomized data","Waldenstrom_macroglobulinemia,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Graft_versus_host_disease_(GVHD),Marginal_zone_lymphoma"
Icotinib monotherapy,Icotinib monotherapy,"Non-small cell lung cancer, EGFR-mutated, all lines of therapy","Non-small_cell_lung_cancer,CNS_carcinoma,Non-small_cell_lung_cancer_EGFR-mutated"
"Idarubicin, then Mitoxantrone, then Idarubicin","Idarubicin, then Mitoxantrone, then Idarubicin",Consolidation after upfront therapy,Acute_promyelocytic_leukemia
"Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA","Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA",Consolidation after upfront therapy,Acute_promyelocytic_leukemia
Idelalisib & Ofatumumab,Idelalisib & Ofatumumab,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Idelalisib & Rituximab,Idelalisib & Rituximab,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Idelalisib monotherapy,Idelalisib monotherapy,"Relapsed or refractory, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Marginal_zone_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Ifosfamide & Methotrexate,Ifosfamide & Methotrexate,"Relapsed or refractory, salvage therapy",CNS_lymphoma
Ifosfamide & Paclitaxel,Ifosfamide & Paclitaxel,"Chemotherapy for advanced, recurrent, or metastatic disease","Endometrial_cancer,Testicular_cancer,Small_cell_lung_cancer"
Ifosfamide & Vinorelbine,Ifosfamide & Vinorelbine,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Ifosfamide monotherapy,Ifosfamide monotherapy,"Persistent, recurrent, or metastatic disease, first-line therapy","Diffuse_large_B-cell_lymphoma,Cervical_cancer,Soft_tissue_sarcoma,Small_cell_lung_cancer,Thymoma,Endometrial_cancer"
Imatinib & LoDAC,Imatinib+LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib  and  LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib and LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib & LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib + LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib/LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & LoDAC,Imatinib / LoDAC,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Imatinib & Prednisone,Imatinib & Prednisone,Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Imatinib monotherapy,Imatinib monotherapy,Relapsed or refractory,"Gastrointestinal_stromal_tumor,B-cell_acute_lymphoblastic_leukemia_Ph-positive,Systemic_mastocytosis,Hypereosinophilic_syndrome,Soft_tissue_sarcoma,Chronic_myelogenous_leukemia,Melanoma"
"Imatinib monotherapy, high dose","Imatinib monotherapy, high dose","Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
"Imatinib monotherapy, intermittent therapy","Imatinib monotherapy, intermittent therapy","Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
"Imatinib monotherapy, planned discontinuation","Imatinib monotherapy, planned discontinuation","Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
"Imatinib, Vincristine, Dexamethasone","Imatinib, Vincristine, Dexamethasone",Upfront induction therapy,B-cell_acute_lymphoblastic_leukemia_Ph-positive
Inotuzumab ozogamicin monotherapy,Inotuzumab ozogamicin monotherapy,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
Interferon alfa monotherapy,Interferon alfa monotherapy,"Chronic phase, first-line therapy","Vascular_sarcoma,Mantle_cell_lymphoma,Chronic_myelogenous_leukemia,Hairy_cell_leukemia"
Interferon alfa-2a & Interleukin-2,Interferon alfa-2a & Interleukin-2,"Metastatic disease, first-line",Renal_cell_carcinoma
Interferon alfa-2a monotherapy,Interferon alfa-2a monotherapy,Adjuvant therapy,"Renal_cell_carcinoma,Melanoma"
Interferon alfa-2b & DLI,Interferon alfa-2b & DLI,"Chronic phase, relapsed or refractory",Chronic_myelogenous_leukemia
Interferon alfa-2b & DLI,DLI,"Chronic phase, relapsed or refractory",Chronic_myelogenous_leukemia
Interferon alfa-2b & Zidovudine,Interferon alfa-2b & Zidovudine,Untreated,Adult_T-cell_leukemia-lymphoma
Interferon alfa-2b monotherapy,HDI,Adjuvant therapy,"Systemic_mastocytosis,Renal_cell_carcinoma,Neuroendocrine_tumors,Melanoma"
Interferon alfa-2b monotherapy,Interferon alfa-2b monotherapy,Adjuvant therapy,"Systemic_mastocytosis,Renal_cell_carcinoma,Neuroendocrine_tumors,Melanoma"
Intraperitoneal 5-FU,Intraperitoneal 5-FU,"Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",Colon_cancer
Intraperitoneal hyperthermic mitomycin,Intraperitoneal hyperthermic mitomycin,"Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",Colon_cancer
Intravenous immunoglobuin monotherapy,Intravenous immunoglobuin monotherapy,Initial therapy,Immune_thrombocytopenia_(ITP)
Intravenous immunoglobuin monotherapy,IVIG,Initial therapy,Immune_thrombocytopenia_(ITP)
Ipilimumab & Nivolumab,Ipilimumab & Nivolumab,Maintenance immunotherapy for metastatic or unresectable disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer,Melanoma"
Ipilimumab monotherapy,Ipilimumab monotherapy,Metastatic or unresectable disease,"Non-small_cell_lung_cancer,Small_cell_lung_cancer,Melanoma"
Irinotecan & Bevacizumab,Irinotecan & Bevacizumab,"Recurrent disease, salvage therapy","Anaplastic_glioma,Glioblastoma"
Irinotecan & Cetuximab,Irinotecan & Cetuximab,"Advanced or metastatic disease, second-line",Colon_cancer_KRAS_wild-type
Irinotecan & Mitomycin,Irinotecan & Mitomycin,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
Irinotecan & Temozolomide,Irinotecan & Temozolomide,Relapsed or refractory or metastatic,Ewings_sarcoma
Irinotecan liposomal monotherapy,Irinotecan liposomal monotherapy,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
Irinotecan monotherapy,Irinotecan monotherapy,"Recurrent disease, salvage therapy","Colon_cancer,Gastric_cancer,Cervical_cancer,Glioblastoma,Esophageal_cancer,Anaplastic_glioma,Small_cell_lung_cancer"
Isotretinoin monotherapy,Isotretinoin monotherapy,"High-risk, consolidation",Neuroblastoma
Ivosidenib monotherapy,Ivosidenib monotherapy,"IDH1 relapsed or refractory, salvage therapy",Acute_myeloid_leukemia_IDH-mutated
Ixazomib & Dexamethasone,Ixazomib & Dexamethasone,Relapsed or refractory,"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
Ixazomib monotherapy,Ixazomib monotherapy,Relapsed or refractory,"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
KTd,KTd,Consolidation after first-line therapy,Multiple_myeloma_consolidation_and_maintenance
"L-Asparaginase, Vincristine, Prednisolone",LVP,Relapsed or refractory,Extranodal_NKT-cell_lymphoma_nasal_type
"L-Asparaginase, Vincristine, Prednisolone","L-Asparaginase, Vincristine, Prednisolone",Relapsed or refractory,Extranodal_NKT-cell_lymphoma_nasal_type
L-glutamine monotherapy,L-glutamine monotherapy,All lines of therapy,Sickle_cell_anemia
LEED,LEED,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
LSG15,LSG15,Untreated,Adult_T-cell_leukemia-lymphoma
"LVP ""Sandwich""","LVP ""Sandwich""",Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
"LVP ""Sandwich""",LVP,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
Lapatinib & Trastuzumab,Lapatinib & Trastuzumab,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
Lenalidomide & Ofatumumab,Lenalidomide & Ofatumumab,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Lenalidomide & Rituximab,Lenalidomide & Rituximab,"First-line therapy, non-randomized or retrospective data","Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Marginal_zone_lymphoma,Transformed_lymphoma"
Lenalidomide monotherapy,Lenalidomide monotherapy,Relapsed or refractory,"Waldenstrom_macroglobulinemia,Adult_T-cell_leukemia-lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Myelodysplastic_syndrome,Diffuse_large_B-cell_lymphoma,Peripheral_T-cell_lymphoma,Multiple_myeloma_relapsedrefractory,Hodgkin_lymphoma,Mantle_cell_lymphoma,Light-chain_(AL)_amyloidosis,Cutaneous_T-cell_lymphoma,Polycythemia_vera,Plasma_cell_leukemia,Marginal_zone_lymphoma,Transformed_lymphoma,Myelofibrosis"
"Lenalidomide, Dexamethasone, Rituximab","Lenalidomide, Dexamethasone, Rituximab","Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
Lenvatinib monotherapy,Lenvatinib monotherapy,First-line therapy for advanced or metastatic disease,"Hepatocellular_carcinoma,Renal_cell_carcinoma,Thyroid_cancer"
Lepirudin monotherapy,Lepirudin monotherapy,All lines of therapy,"Venous_thromboembolism_(VTE),Heparin-induced_thrombocytopenia_(HIT)"
LoDAC,LDAC,"First-line induction therapy, older or ""unfit"" patients","Acute_myeloid_leukemia,Myelodysplastic_syndrome"
LoDAC,LoDAC,"First-line induction therapy, older or ""unfit"" patients","Acute_myeloid_leukemia,Myelodysplastic_syndrome"
LoDAC & Venetoclax,LoDAC/Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC + Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC  and  Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC and Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC / Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC+Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
LoDAC & Venetoclax,LoDAC & Venetoclax,"First-line induction therapy, older or ""unfit"" patients",Acute_myeloid_leukemia
Lomustine monotherapy,Lomustine monotherapy,"Recurrent disease, non-curative therapy, randomized data",Glioblastoma
"Lomustine, Methotrexate, Procarbazine",MCP,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
"Lomustine, Methotrexate, Procarbazine","Lomustine, Methotrexate, Procarbazine","Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
"Lomustine, Methotrexate, Procarbazine, Methylprednisolone","Lomustine, Methotrexate, Procarbazine, Methylprednisolone","Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
"Lomustine, Vincristine, Prednisone","Lomustine, Vincristine, Prednisone",Adjuvant therapy,Anaplastic_glioma
Lorlatinib monotherapy,Lorlatinib monotherapy,"Advanced or metastatic disease, ALK inhibitor-exposed","Non-small_cell_lung_cancer_ROS1-positive,Non-small_cell_lung_cancer_ALK-positive"
Low-dose Interleukin-2,LD IL/2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Low-dose Interleukin-2,Low-dose Interleukin-2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Low-dose Interleukin-2,LDIL2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Low-dose Interleukin-2,LD IL2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Low-dose Interleukin-2,LD IL-2,Metastatic or unresectable disease,"Renal_cell_carcinoma,Melanoma"
Lutetium Lu 177 dotatate & Octreotide LAR,Lutetium Lu 177 dotatate & Octreotide LAR,All lines of therapy,Neuroendocrine_tumors
M-BCD,MBCD,Neoadjuvant therapy,Osteosarcoma
M-BCD,M-BCD,Neoadjuvant therapy,Osteosarcoma
M-BCD,M/BCD,Neoadjuvant therapy,Osteosarcoma
M-DEX,M-DEX,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
M-DEX,MDEX,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
M-DEX,M/DEX,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
M-EI,MEI,Neoadjuvant therapy,Osteosarcoma
M-EI,M-EI,Neoadjuvant therapy,Osteosarcoma
M-EI,M/EI,Neoadjuvant therapy,Osteosarcoma
M-TIP,M-TIP,Upfront therapy for disseminated disease,Testicular_cancer
M-TIP,M/TIP,Upfront therapy for disseminated disease,Testicular_cancer
M-TIP,MTIP,Upfront therapy for disseminated disease,Testicular_cancer
MA,MA,Neoadjuvant therapy,Osteosarcoma
MA-BCD,MABCD,Neoadjuvant therapy,Osteosarcoma
MA-BCD,MA/BCD,Neoadjuvant therapy,Osteosarcoma
MA-BCD,MA-BCD,Neoadjuvant therapy,Osteosarcoma
MA-BCD/AP,MABCDAP,Adjuvant therapy,Osteosarcoma
MA-BCD/AP,MABCD/AP,Adjuvant therapy,Osteosarcoma
MA-BCD/AP,MA/BCD/AP,Adjuvant therapy,Osteosarcoma
MA-BCD/AP,MA-BCD/AP,Adjuvant therapy,Osteosarcoma
MAID,MAID,"Locally advanced or metastatic disease, combination regimens",Soft_tissue_sarcoma
MAP,MAP,Neoadjuvant therapy,Osteosarcoma
MAPI,MAPI,Neoadjuvant therapy,Osteosarcoma
MAPIE,MAPIE,Adjuvant therapy,Osteosarcoma
MATRix,MATRix,"Upfront therapy, randomized data",CNS_lymphoma
MCF,MCF,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
MCP,MCP,"First-line therapy, randomized data","Marginal_zone_lymphoma,Mantle_cell_lymphoma"
MCV,MCV,Neoadjuvant chemotherapy,Bladder_cancer
MCV,CMV,Neoadjuvant chemotherapy,Bladder_cancer
MEC,MEC,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
MEC,MICE,"Upfront induction therapy, standard and older ""fit"" patients",Acute_myeloid_leukemia
MESA,MESA,Untreated,Extranodal_NKT-cell_lymphoma_nasal_type
MINE,MINE,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
MOPP,MOPP,"Untreated, advanced stage",Hodgkin_lymphoma
MOPP-ABV,MOPP-ABV,"Untreated, early-stage favorable (ESF)",Hodgkin_lymphoma
MOPP-ABV,MOPP/ABV,"Untreated, early-stage favorable (ESF)",Hodgkin_lymphoma
MOPP-ABV,MOPPABV,"Untreated, early-stage favorable (ESF)",Hodgkin_lymphoma
MP,MP,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
MPR,MPL,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
MPR,MPR,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
MPT,MPT,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
MPV,MPV,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
MRD,MRD,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
MRD,L/M/Dex,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
MRD,L-M-Dex,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
MRD,LMDex,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
MT-R,MT/R,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
MT-R,MT-R,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
MT-R,MTR,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
MVAC,MVAC,Neoadjuvant chemotherapy,Bladder_cancer
"MVAC, dose-dense",AMVAC,Neoadjuvant chemotherapy,Bladder_cancer
"MVAC, dose-dense",ddMVAC,Neoadjuvant chemotherapy,Bladder_cancer
"MVAC, dose-dense","MVAC, dose-dense",Neoadjuvant chemotherapy,Bladder_cancer
MVBP,MVBP,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
Melphalan & TBI,Melphalan+TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan/TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan  and  TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan & TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan and TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan / TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan & TBI,Melphalan + TBI,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
Melphalan monotherapy,Melphalan monotherapy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
"Melphalan, then auto HSCT","Melphalan, then auto HSCT",Consolidation after first-line therapy,"Plasma_cell_leukemia,Light-chain_(AL)_amyloidosis"
Mepolizumab monotherapy,Mepolizumab monotherapy,All lines of therapy,Hypereosinophilic_syndrome
Mercaptopurine & Methotrexate,Mercaptopurine & Methotrexate,Maintenance after upfront therapy,Acute_promyelocytic_leukemia
Mercaptopurine & WBRT,Mercaptopurine & WBRT,CNS prophylaxis,CNS_leukemia
"Mercaptopurine, Methotrexate, Vinblastine, Prednisolone","Mercaptopurine, Methotrexate, Vinblastine, Prednisolone","Relapsed or refractory, maintenance",Langerhans_cell_histiocytosis
Methotrexate & Prednisone,Methotrexate & Prednisone,Initial therapy,Large_granular_lymphocytic_leukemia
Methotrexate & Rituximab,Methotrexate & Rituximab,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
Methotrexate & Vincristine,Methotrexate & Vincristine,Adjuvant therapy,Osteosarcoma
Methotrexate monotherapy,Methotrexate monotherapy,"Upfront therapy, randomized data","Cutaneous_T-cell_lymphoma,CNS_lymphoma,Gestational_trophoblastic_neoplasia,Head_and_neck_cancer"
"Methotrexate, Tacrolimus, Tocilizumab","Methotrexate, Tacrolimus, Tocilizumab",Prevention,Graft_versus_host_disease_(GVHD)
"Methotrexate, Tacrolimus, Vorinostat","Methotrexate, Tacrolimus, Vorinostat",Prevention,Graft_versus_host_disease_(GVHD)
"Methotrexate, Vinblastine, Prednisone","Methotrexate, Vinblastine, Prednisone",Untreated,Langerhans_cell_histiocytosis
"Methotrexate, then Cytarabine","Methotrexate, then Cytarabine","Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
"Methotrexate, then Cytarabine & Thiotepa","Methotrexate, then Cytarabine & Thiotepa","Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
Methylprednisolone monotherapy,Methylprednisolone monotherapy,Relapsed or refractory,Thrombotic_thrombocytopenic_purpura
Midostaurin monotherapy,Midostaurin monotherapy,"Relapsed or refractory, salvage therapy","Acute_myeloid_leukemia_FLT3-positive,Myelodysplastic_syndrome"
Mini-BEAM,Mini-BEAM,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Mini-BEAM,Mini/BEAM,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Mini-BEAM,MiniBEAM,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Mitomycin monotherapy,Mitomycin monotherapy,Intravesical chemotherapy,Bladder_cancer
Mitotane & EDP,Mitotane and EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane+EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane / EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane & EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane  and  EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane/EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & EDP,Mitotane + EDP,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane & Streptozocin,Mitotane & Streptozocin,"Recurrent, locally advanced, or metastatic disease",Adrenocortical_carcinoma
Mitotane monotherapy,Mitotane monotherapy,Adjuvant therapy,Adrenocortical_carcinoma
Mitoxantrone monotherapy,Mitoxantrone monotherapy,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
Mogamulizumab monotherapy,Mogamulizumab monotherapy,Relapsed or refractory,"Cutaneous_T-cell_lymphoma,Peripheral_T-cell_lymphoma"
Moxetumomab pasudotox monotherapy,Moxetumomab pasudotox monotherapy,Relapsed or refractory,Hairy_cell_leukemia
Mycophenolate mofetil monotherapy,Mycophenolate mofetil monotherapy,Relapsed or refractory,Immune_thrombocytopenia_(ITP)
Necitumumab monotherapy,Necitumumab monotherapy,Maintenance after first-line therapy,Non-small_cell_lung_cancer
Neratinib & Paclitaxel,Neratinib & Paclitaxel,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
Neratinib monotherapy,Neratinib monotherapy,All lines of therapy,"ERBB3_(HER3),ERBB2_(HER2)"
Nilotinib monotherapy,Nilotinib monotherapy,Maintenance after upfront therapy,"Hypereosinophilic_syndrome,Systemic_mastocytosis,Chronic_myelogenous_leukemia,B-cell_acute_lymphoblastic_leukemia_Ph-positive"
Nimustine & RT,Nimustine+RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine + RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine/RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine and RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine & RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine  and  RT,"Adjuvant therapy, standard patients",Glioblastoma
Nimustine & RT,Nimustine / RT,"Adjuvant therapy, standard patients",Glioblastoma
Niraparib monotherapy,Niraparib monotherapy,Maintenance after second-line therapy for platinum-sensitive disease,Ovarian_cancer
Nivolumab monotherapy,Nivolumab monotherapy,"Metastatic disease, subsequent lines of therapy","Hepatocellular_carcinoma,Non-small_cell_lung_cancer,Gastric_cancer,Renal_cell_carcinoma,Hodgkin_lymphoma,Small_cell_lung_cancer,Anal_cancer,Head_and_neck_cancer,Melanoma"
Nordic FLOX,FLOX,"Advanced or metastatic disease, first-line",Colon_cancer
Nordic FLOX,Nordic FLOX,"Advanced or metastatic disease, first-line",Colon_cancer
O-CHOP,O/CHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
O-CHOP,O-CHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
O-CHOP,OCHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
O-ESHAP,O-ESHAP,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
O-ESHAP,O/ESHAP,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
O-ESHAP,OESHAP,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
O-FC,O/FC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
O-FC,OFC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
O-FC,O-FC,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
O-miniCHOP,OminiCHOP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
O-miniCHOP,O/miniCHOP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
O-miniCHOP,O-miniCHOP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
OEPA,OEPA,"Untreated, pediatric",Hodgkin_lymphoma
OFAR,OFAR,"Relapsed or refractory, non-randomized or retrospective data","Transformed_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
OLF,OLF,"Metastatic or locally advanced disease, first-line","Gastric_cancer,Pancreatic_cancer"
OLF,FLO,"Metastatic or locally advanced disease, first-line","Gastric_cancer,Pancreatic_cancer"
OPPA,OPPA,"Untreated, pediatric",Hodgkin_lymphoma
OXAFAFU,OXAFAFU,"Advanced or metastatic disease, first-line",Colon_cancer
Obinutuzumab monotherapy,Obinutuzumab monotherapy,"First-line therapy, randomized data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Ofatumumab monotherapy,Ofatumumab monotherapy,Consolidation and/or maintenance after first-line therapy,"Diffuse_large_B-cell_lymphoma,Waldenstrom_macroglobulinemia,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
Olaparib monotherapy,Olaparib monotherapy,"Advanced or metastatic disease, all lines of therapy","Ovarian_cancer,Prostate_cancer,Breast_cancer_BRCA-mutated,Pancreatic_cancer"
Osimertinib monotherapy,Osimertinib monotherapy,"Non-small cell lung cancer, EGFR-mutated, all lines of therapy","CNS_carcinoma,Non-small_cell_lung_cancer_EGFR-mutated"
Ox-P,Ox-P,"Relapsed or refractory, non-randomized or retrospective data",Marginal_zone_lymphoma
Ox-P,Ox/P,"Relapsed or refractory, non-randomized or retrospective data",Marginal_zone_lymphoma
Ox-P,OxP,"Relapsed or refractory, non-randomized or retrospective data",Marginal_zone_lymphoma
Oxaliplatin & Bevacizumab,Oxaliplatin & Bevacizumab,Subsequent lines of therapy,Testicular_cancer
Oxaliplatin monotherapy,Oxaliplatin monotherapy,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
PAC,CAP,Neoadjuvant therapy for borderline resectable disease,Thymoma
PAC,PAC,Neoadjuvant therapy for borderline resectable disease,Thymoma
PAD,PAd,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
PAD,PAD,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
PAD,BDD,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
PAD,VAD,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
PCE,PCE,All lines of therapy,Adenocarcinoma_of_unknown_primary
PCF,PCF,Neoadjuvant induction therapy,"Esophageal_cancer,SCC_of_unknown_primary,Penile_cancer,Head_and_neck_cancer"
PCO,PCO,"First-line therapy, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
PCP,PCP,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
PCR,PCR,"First-line therapy, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Marginal_zone_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma"
PCV,PCV,Adjuvant therapy,"Low-grade_glioma,Anaplastic_glioma,Glioblastoma"
PGC,PGC,Adjuvant chemotherapy,Bladder_cancer
PGC,PCG,Adjuvant chemotherapy,Bladder_cancer
PVAG,PVAG,"Untreated, elderly",Hodgkin_lymphoma
PVD,PVD,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
PVeBV,PVeBV,Upfront therapy for disseminated disease,Testicular_cancer
PVeBV,VBEP,Upfront therapy for disseminated disease,Testicular_cancer
Paclitaxel & Bevacizumab,Paclitaxel & Bevacizumab,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Paclitaxel & Pazopanib,Paclitaxel & Pazopanib,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Paclitaxel & RT,Paclitaxel  and  RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel & RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel/RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel+RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel / RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel and RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & RT,Paclitaxel + RT,Induction chemoradiotherapy,"Head_and_neck_cancer,Bladder_cancer"
Paclitaxel & Ramucirumab,Paclitaxel & Ramucirumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
Paclitaxel & Topotecan,Paclitaxel & Topotecan,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
Paclitaxel monotherapy,Paclitaxel monotherapy,"Locally advanced or metastatic disease, subsequent lines","Vulvar_cancer,Penile_cancer,Gastric_cancer,Ovarian_cancer,Bladder_cancer,Cervical_cancer,Endometrial_cancer,Esophageal_cancer,Small_cell_lung_cancer,Breast_cancer_triple_negative,Vascular_sarcoma,Melanoma"
"Paclitaxel monotherapy, dose-dense (q2wk)","Paclitaxel monotherapy, dose-dense (q2wk)",Neoadjuvant chemotherapy,Breast_cancer
"Paclitaxel monotherapy, dose-dense (q2wk)",ddT,Neoadjuvant chemotherapy,Breast_cancer
"Paclitaxel monotherapy, weekly","Paclitaxel monotherapy, weekly",Neoadjuvant chemotherapy,Breast_cancer
"Paclitaxel, Topotecan, Bevacizumab","Paclitaxel, Topotecan, Bevacizumab","Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP/Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP and Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP&Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP+Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP & Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TPBev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, Topotecan, Bevacizumab",TP / Bev,"Persistent, recurrent, or metastatic disease, first-line therapy",Cervical_cancer
"Paclitaxel, nanoparticle albumin-bound monotherapy","Paclitaxel, nanoparticle albumin-bound monotherapy","Locally advanced or metastatic disease, subsequent lines","Gastric_cancer,Ovarian_cancer,Bladder_cancer,Breast_cancer,Pancreatic_cancer,Melanoma"
Panitumumab monotherapy,Panitumumab monotherapy,"Advanced or metastatic disease, subsequent lines of therapy","Colon_cancer_KRAS_wild-type,Penile_cancer"
Panobinostat & Rituximab,Panobinostat & Rituximab,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
Panobinostat monotherapy,Panobinostat monotherapy,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Hodgkin_lymphoma,Waldenstrom_macroglobulinemia"
Pazopanib monotherapy,Pazopanib monotherapy,Metastatic or unresectable disease,"Gastrointestinal_stromal_tumor,Ovarian_cancer,Renal_cell_carcinoma,Soft_tissue_sarcoma,Thyroid_cancer"
Peginterferon alfa-2a monotherapy,Peginterferon alfa-2a monotherapy,First-line therapy,"Hypereosinophilic_syndrome,Essential_thrombocythemia,Polycythemia_vera"
Peginterferon alfa-2b monotherapy,Peginterferon alfa-2b monotherapy,Adjuvant therapy,Melanoma
Pembrolizumab monotherapy,Pembrolizumab monotherapy,"Metastatic disease, subsequent lines of therapy","Hepatocellular_carcinoma,Merkel_cell_carcinoma,Non-small_cell_lung_cancer,Primary_mediastinal_B-cell_lymphoma,Gastric_cancer,Cervical_cancer,Bladder_cancer,Cholangiocarcinoma,Hodgkin_lymphoma,MSI-H_or_dMMR,Anal_cancer,Head_and_neck_cancer,Endometrial_cancer,Transformed_lymphoma,Melanoma"
Pemetrexed & Bevacizumab,Pemetrexed & Bevacizumab,"Advanced or metastatic disease, first-line, elderly or poor performance status",Non-small_cell_lung_cancer
Pemetrexed monotherapy,Pemetrexed monotherapy,"Locally advanced or metastatic disease, subsequent lines","Non-small_cell_lung_cancer,Ovarian_cancer,Bladder_cancer,Cervical_cancer,Mesothelioma"
Pentostatin monotherapy,Pentostatin monotherapy,Untreated,Hairy_cell_leukemia
Pertuzumab & Trastuzumab,Pertuzumab & Trastuzumab,Maintenance for metastatic or unresectable disease,"ERBB2_(HER2),Breast_cancer_HER2-positive"
Pipobroman monotherapy,Pipobroman monotherapy,"Relapsed, refractory, or intolerant",Polycythemia_vera
Pirarubicin monotherapy,Pirarubicin monotherapy,Intravesical chemotherapy,Bladder_cancer
Pixantrone monotherapy,Pixantrone monotherapy,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
PomCyDex,PCD,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
PomCyDex,PomCyDex,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
Pomalidomide & Dexamethasone,Pomalidomide & Dexamethasone,Relapsed or refractory,"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
Pomalidomide & Prednisone,Pomalidomide & Prednisone,Maintenance after second-line therapy,"Multiple_myeloma_relapsedrefractory,Myelofibrosis"
Pomalidomide monotherapy,Pomalidomide monotherapy,"Relapsed or refractory, randomized data","Multiple_myeloma_relapsedrefractory,Myelofibrosis"
"Pomalidomide, Dexamethasone, Daratumumab","Pomalidomide, Dexamethasone, Daratumumab","Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
Ponatinib monotherapy,Ponatinib monotherapy,Relapsed or refractory,"Chronic_myelogenous_leukemia,B-cell_acute_lymphoblastic_leukemia_Ph-positive"
Pralatrexate monotherapy,Pralatrexate monotherapy,Relapsed or refractory,"Cutaneous_T-cell_lymphoma,Peripheral_T-cell_lymphoma"
Prednisolone monotherapy,Prednisolone monotherapy,"Acquired hemophilia A, all lines of therapy",Acquired_coagulopathy
Prednisone monotherapy,Prednisone monotherapy,"Acquired hemophilia A, all lines of therapy","Acquired_coagulopathy,Immune_thrombocytopenia_(ITP),Myelofibrosis"
Procarbazine monotherapy,Procarbazine monotherapy,Consolidation and/or maintenance after upfront therapy,"CNS_lymphoma,Glioblastoma"
R-BAC,R/BAC,"Relapsed or refractory, non-randomized or retrospective data","Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
R-BAC,R-BAC,"Relapsed or refractory, non-randomized or retrospective data","Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
R-BAC,RBAC,"Relapsed or refractory, non-randomized or retrospective data","Mantle_cell_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL)"
R-BEAM,RBEAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-BEAM,R/BEAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-BEAM,R-BEAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-BL,R/BL,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma"
R-BL,R-BL,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma"
R-BL,RBL,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma"
R-CDOP,R-CDOP,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,HIV-associated_lymphoma"
R-CDOP,R/CDOP,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,HIV-associated_lymphoma"
R-CDOP,RCDOP,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,HIV-associated_lymphoma"
R-CDOP,DRCOP,"Untreated, non-randomized or retrospective data","Diffuse_large_B-cell_lymphoma,HIV-associated_lymphoma"
R-CEOP90 (Epirubicin),R-CEOP90,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-CEOP90 (Epirubicin),R/CEOP90,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-CEOP90 (Epirubicin),R-CEOP90 (Epirubicin),"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-CEOP90 (Epirubicin),RCEOP90,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-CHOEP-14,RCHOEP14,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-CHOEP-14,R/CHOEP/14,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-CHOEP-14,R-CHOEP-14,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-CHOP,CHOPR,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,R/CHOP/21,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,RCHOP,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,R-CHOP,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,R/CHOP,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,CHOP-R,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,RCHOP21,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,R-CHOP-21,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP,CHOP/R,"Untreated, randomized data","Waldenstrom_macroglobulinemia,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Post-transplant_lymphoproliferative_disorder,HIV-associated_lymphoma,Marginal_zone_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP-14,R/CHOP/14,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP-14,RCHOP14,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHOP-14,R-CHOP-14,"Untreated, randomized data","Diffuse_large_B-cell_lymphoma,Mantle_cell_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-CHVP+I,R-CHVP & I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVP/I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVPI,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVP and I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVP&I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R/CHVP+I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,RCHVPI,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,RCHVP+I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVP / I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CHVP+I,R-CHVP+I,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-CMD,RCMD,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
R-CMD,R/CMD,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
R-CMD,R-CMD,"Advanced disease, first-line therapy, non-randomized or retrospective data",Follicular_lymphoma
R-CODOX-M,R-CODOX-M,Upfront therapy,HIV-associated_lymphoma
R-CODOX-M,R/CODOX/M,Upfront therapy,HIV-associated_lymphoma
R-CODOX-M,RCODOXM,Upfront therapy,HIV-associated_lymphoma
R-CODOX-M/R-IVAC,R-CODOX-M/R-IVAC,Upfront therapy,HIV-associated_lymphoma
R-CP,RCP,All lines of therapy,Post-transplant_lymphoproliferative_disorder
R-CP,R-CP,All lines of therapy,Post-transplant_lymphoproliferative_disorder
R-CP,R/CP,All lines of therapy,Post-transplant_lymphoproliferative_disorder
R-CVEP,R-CVEP,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-CVEP,R/CVEP,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-CVEP,RCVEP,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-CVP,R/CVP,"Advanced disease, first-line therapy, randomized data","Hodgkin_lymphoma_nodular_lymphocyte-predominant,Mantle_cell_lymphoma,Follicular_lymphoma,Marginal_zone_lymphoma"
R-CVP,R-CVP,"Advanced disease, first-line therapy, randomized data","Hodgkin_lymphoma_nodular_lymphocyte-predominant,Mantle_cell_lymphoma,Follicular_lymphoma,Marginal_zone_lymphoma"
R-CVP,RCVP,"Advanced disease, first-line therapy, randomized data","Hodgkin_lymphoma_nodular_lymphocyte-predominant,Mantle_cell_lymphoma,Follicular_lymphoma,Marginal_zone_lymphoma"
R-DHAC,RDHAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAC,R-DHAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAC,R/DHAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAOx,RDHAOx,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAOx,R/DHAOx,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAOx,R-DHAOx,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-DHAP,R/DHAP,"First-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-DHAP,RDHAP,"First-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-DHAP,R-DHAP,"First-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-DexaBEAM,RDexaBEAM,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
R-DexaBEAM,R/DexaBEAM,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
R-DexaBEAM,R-DexaBEAM,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
R-EPOCH,R/EPOCH,Untreated,"Hodgkin_lymphoma_nodular_lymphocyte-predominant,Transformed_lymphoma"
R-EPOCH,REPOCH,Untreated,"Hodgkin_lymphoma_nodular_lymphocyte-predominant,Transformed_lymphoma"
R-EPOCH,R-EPOCH,Untreated,"Hodgkin_lymphoma_nodular_lymphocyte-predominant,Transformed_lymphoma"
"R-EPOCH, dose-escalated","R-EPOCH, dose-escalated",Upfront therapy,HIV-associated_lymphoma
"R-EPOCH, dose-escalated",R/EPOCH,Upfront therapy,HIV-associated_lymphoma
"R-EPOCH, dose-escalated",REPOCH,Upfront therapy,HIV-associated_lymphoma
"R-EPOCH, dose-escalated",R-EPOCH,Upfront therapy,HIV-associated_lymphoma
R-FCM,RFCM,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
R-FCM,R/FCM,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
R-FCM,R-FCM,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
R-FM,R-FM,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FM,R/FM,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FM,RFM,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FM,FMR,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FND,RFND,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FND,R/FND,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-FND,R-FND,"Advanced disease, first-line therapy, randomized data",Follicular_lymphoma
R-GDP,RGDP,"Relapsed or refractory, salvage therapy","Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-GDP,R/GDP,"Relapsed or refractory, salvage therapy","Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-GDP,R-GDP,"Relapsed or refractory, salvage therapy","Transformed_lymphoma,Primary_mediastinal_B-cell_lymphoma"
R-GemOx,RGemOx,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-GemOx,R/GemOx,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-GemOx,R-GemOx,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
R-HiDAC,RHiDAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-HiDAC,R/HiDAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-HiDAC,R-HiDAC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-IFE,RIFE,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-IFE,R/IFE,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-IFE,R-IFE,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-INO,RINO,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Follicular_lymphoma"
R-INO,R-INO,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Follicular_lymphoma"
R-INO,R/INO,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Follicular_lymphoma"
R-M-CHOP,RMCHOP,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-M-CHOP,R-M-CHOP,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-M-CHOP,R/M/CHOP,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-MCP,R/MCP,"Upfront therapy, non-randomized or retrospective data","CNS_lymphoma,Follicular_lymphoma"
R-MCP,R-MCP,"Upfront therapy, non-randomized or retrospective data","CNS_lymphoma,Follicular_lymphoma"
R-MCP,RMCP,"Upfront therapy, non-randomized or retrospective data","CNS_lymphoma,Follicular_lymphoma"
R-MP,R-MP,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MP,R/MP,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MP,RMP,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MPV,R-MPV,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MPV,R/MPV,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MPV,RMPV,"Upfront therapy, non-randomized or retrospective data",CNS_lymphoma
R-MegaCHOP-14,R-MegaCHOP-14,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-NIMP,RNIMP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-NIMP,R-NIMP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-NIMP,R/NIMP,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
R-TBI/Cy,R-TBI/Cy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-TBI/Cy,RTBI/Cy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-TBI/Cy,RTBICy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-TBI/Cy,R/TBI/Cy,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
R-VAD+C,R-VAD / C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,RVAD+C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VAD&C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,RVADC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VAD+C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VAD and C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R/VAD+C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VAD & C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VAD/C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-VAD+C,R-VADC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
R-miniCEOP,R-miniCEOP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-miniCEOP,R/miniCEOP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
R-miniCEOP,RminiCEOP,"Untreated, randomized data",Diffuse_large_B-cell_lymphoma
RABVD,RABVD,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
RD,RD,Relapsed or refractory,"POEMS,Light-chain_(AL)_amyloidosis"
RICER,RICER,"Untreated, non-randomized or retrospective data",Diffuse_large_B-cell_lymphoma
"RT, then Carmustine","RT, then Carmustine",Adjuvant therapy,Anaplastic_glioma
"RT, then Temozolomide","RT, then Temozolomide",Adjuvant therapy,Anaplastic_glioma
RVD,VRd,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
RVD,RVD,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
RVD,VDR,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
RVD,VRD,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
RVDC,VDCR,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
RVDC,RVDC,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
RVR,RVR,"Relapsed or refractory, non-randomized or retrospective data",Waldenstrom_macroglobulinemia
Rabbit ATG,Rabbit ATG,Prevention,Graft_versus_host_disease_(GVHD)
Radotinib monotherapy,Radotinib monotherapy,"Chronic phase, first-line therapy",Chronic_myelogenous_leukemia
Ramucirumab monotherapy,Ramucirumab monotherapy,Metastatic or locally advanced disease (non-radiation/surgery candidate),"Esophageal_cancer,Gastric_cancer"
Rd,RevDex,Maintenance after first-line therapy,"Multiple_myeloma_relapsedrefractory,Plasma_cell_leukemia,Multiple_myeloma_induction,Light-chain_(AL)_amyloidosis"
Rd,LenDex,Maintenance after first-line therapy,"Multiple_myeloma_relapsedrefractory,Plasma_cell_leukemia,Multiple_myeloma_induction,Light-chain_(AL)_amyloidosis"
Rd,Rd,Maintenance after first-line therapy,"Multiple_myeloma_relapsedrefractory,Plasma_cell_leukemia,Multiple_myeloma_induction,Light-chain_(AL)_amyloidosis"
Regorafenib monotherapy,Regorafenib monotherapy,"Advanced or metastatic disease, subsequent lines of therapy","Hepatocellular_carcinoma,Gastrointestinal_stromal_tumor,Colon_cancer,Gastric_cancer,Renal_cell_carcinoma,Soft_tissue_sarcoma"
RhIG monotherapy,RhIG,Initial therapy,Immune_thrombocytopenia_(ITP)
RhIG monotherapy,RhIG monotherapy,Initial therapy,Immune_thrombocytopenia_(ITP)
RiPAD+C,RiPAD/C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPAD&C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPAD and C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPAD & C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPAD / C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPADC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
RiPAD+C,RiPAD+C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
Rituximab monotherapy,Rituximab monotherapy,"Acquired hemophilia A, all lines of therapy","Hodgkin_lymphoma_nodular_lymphocyte-predominant,Waldenstrom_macroglobulinemia,CNS_lymphoma,Chronic_lymphocytic_leukemia_(CLLSLL),Follicular_lymphoma,Immune_thrombocytopenia_(ITP),Diffuse_large_B-cell_lymphoma,Hairy_cell_leukemia,Acquired_coagulopathy,Hodgkin_lymphoma,Inherited_coagulopathy,Mantle_cell_lymphoma,Cold_agglutinin_disease,Thrombotic_thrombocytopenic_purpura,HIV-associated_lymphoma,Marginal_zone_lymphoma,Castleman_disease"
"Rituximab monotherapy, abbreviated course","Rituximab monotherapy, abbreviated course",Consolidation after first-line therapy,Follicular_lymphoma
"Rituximab monotherapy, extended course","Rituximab monotherapy, extended course",Maintenance after first-line therapy,Follicular_lymphoma
"Rituximab monotherapy, very extended course","Rituximab monotherapy, very extended course",Maintenance after first-line therapy,Follicular_lymphoma
Rivaroxaban monotherapy,Rivaroxaban monotherapy,All lines of therapy,"Antiphospholipid_antibody_syndrome,Venous_thromboembolism_(VTE),Heparin-induced_thrombocytopenia_(HIT)"
Romidepsin monotherapy,Romidepsin monotherapy,Relapsed or refractory,"Cutaneous_T-cell_lymphoma,Peripheral_T-cell_lymphoma"
Rucaparib monotherapy,Rucaparib monotherapy,"Second-line therapy for relapsed or recurrent disease, platinum-sensitive",Ovarian_cancer
Ruxolitinib monotherapy,Ruxolitinib monotherapy,"Relapsed or refractory, subsequent lines of therapy","Chronic_lymphocytic_leukemia_(CLLSLL),Acute_myeloid_leukemia,Hypereosinophilic_syndrome,Polycythemia_vera,Essential_thrombocythemia,Myelofibrosis"
S-1 monotherapy,S-1 monotherapy,"Advanced or metastatic disease, first-line","Non-small_cell_lung_cancer,Colon_cancer,Gastric_cancer,Rectal_cancer,Pancreatic_cancer"
SC-EPOCH-RR,SC-EPOCH-RR,Upfront therapy,HIV-associated_lymphoma
SMILE,SMILE,Untreated,"NKT-cell_lymphoma,Extranodal_NKT-cell_lymphoma_nasal_type"
SOX,SOX,"Advanced or metastatic disease, first-line",Colon_cancer
Siltuximab monotherapy,Siltuximab monotherapy,"HHV-8-negative/""Idiopathic"" multicentric Castleman disease, all lines of therapy",Castleman_disease
Sipuleucel-T monotherapy,Sipuleucel-T monotherapy,Immunotherapy for metastatic castrate-resistant disease,Prostate_cancer
Sirolimus & Prednisone,Sirolimus & Prednisone,All lines of therapy,Erdheim-Chester_disease
Sirolimus monotherapy,Sirolimus monotherapy,Relapsed or refractory,"Autoimmune_cytopenias,Castleman_disease"
"Sirolimus, Tacrolimus, Prednisone","Sirolimus, Tacrolimus, Prednisone","Treatment, cGVHD, all lines of therapy",Graft_versus_host_disease_(GVHD)
Sonidegib monotherapy,Sonidegib monotherapy,"Advanced or metastatic disease, all lines of therapy",Cutaneous_basal_cell_carcinoma
Sorafenib monotherapy,Sorafenib monotherapy,Maintenance after first-line therapy,"Hepatocellular_carcinoma,Non-small_cell_lung_cancer,Acute_myeloid_leukemia,Renal_cell_carcinoma,Soft_tissue_sarcoma,Acute_myeloid_leukemia_FLT3-positive,Thyroid_cancer"
Stanford V,Stanford V,Upfront therapy,"Hodgkin_lymphoma,HIV-associated_lymphoma"
Sunitinib monotherapy,Sunitinib monotherapy,Metastatic or unresectable disease,"Gastrointestinal_stromal_tumor,Pancreatic_NET,Renal_cell_carcinoma,Testicular_cancer,Small_cell_lung_cancer,Thymoma,Thyroid_cancer"
TAC (Taxotere),ATC,Neoadjuvant chemotherapy,Breast_cancer
TAC (Taxotere),TAC,Neoadjuvant chemotherapy,Breast_cancer
TAC (Taxotere),TAC (Taxotere),Neoadjuvant chemotherapy,Breast_cancer
TACE,TACE,Local therapy,Hepatocellular_carcinoma
"TACE, then 5-FU","TACE, then 5-FU",First-line therapy for advanced or metastatic disease,Hepatocellular_carcinoma
TAD,TAD,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
TAM6,TAM,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
TAM6,TAM6,"High dose therapy conditioning regimens, all lines of therapy",Autologous_HSCT
TCHP (Taxotere),TCHP,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
TCHP (Taxotere),TCHP (Taxotere),Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
"TFC, then allo HSCT","TFC, then allo HSCT",Consolidation and/or maintenance after upfront therapy,Peripheral_T-cell_lymphoma
"TFC, then allo HSCT",TFC,Consolidation and/or maintenance after upfront therapy,Peripheral_T-cell_lymphoma
TH (Taxol),TH (Taxol),Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
TH (Taxol),T-T,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
TH (Taxol),T/T,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
TIP,TIP,Neoadjuvant chemotherapy,"Testicular_cancer,Penile_cancer"
TLI & ATG,TLI / ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI & ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI and ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLIATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI + ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI/ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI+ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TLI & ATG,TLI  and  ATG,"Reduced-intensity conditioning (RIC), all lines of therapy",Allogeneic_HSCT
TT4,TT4,Initial therapy,Immune_thrombocytopenia_(ITP)
TTR,TTR,"Relapsed or refractory, further lines of therapy",Diffuse_large_B-cell_lymphoma
Tagraxofusp monotherapy,Tagraxofusp monotherapy,All lines of therapy,Blastic_plasmacytoid_dendritic_cell_neoplasm
Talazoparib monotherapy,Talazoparib monotherapy,"Advanced or metastatic disease, all lines of therapy",Breast_cancer_BRCA-mutated
Talimogene laherparepvec monotherapy,Talimogene laherparepvec monotherapy,Local therapy,Melanoma
Tamibarotene monotherapy,Tamibarotene monotherapy,"Relapsed or refractory, salvage induction therapy",Acute_promyelocytic_leukemia
Tegafur & Uracil,Tegafur + Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur/Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur / Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur  and  Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur and Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur+Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
Tegafur & Uracil,Tegafur & Uracil,Adjuvant therapy,"Head_and_neck_cancer,Non-small_cell_lung_cancer"
"Tegafur, Uracil, Folinic acid",UFT  &  LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid","Tegafur, Uracil, Folinic acid",Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT  /  LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT  and  LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT + LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT / LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT  LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFT & LV,Adjuvant therapy,Colon_cancer
"Tegafur, Uracil, Folinic acid",UFTLV,Adjuvant therapy,Colon_cancer
Temozolomide & Bevacizumab,Temozolomide & Bevacizumab,Metastatic or unresectable disease,"Pancreatic_NET,Melanoma"
Temozolomide & NovoTTF-100A,Temozolomide & NovoTTF-100A,Maintenance after first-line therapy,Glioblastoma
Temozolomide & RT,Temozolomide  and  RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide / RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide + RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide+RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide & RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide and RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
Temozolomide & RT,Temozolomide/RT,Adjuvant therapy,"Anaplastic_glioma,Glioblastoma"
"Temozolomide & RT, then Temozolomide","Temozolomide & RT, then Temozolomide",Adjuvant therapy,Anaplastic_glioma
Temozolomide & Thalidomide,Temozolomide & Thalidomide,All lines of therapy,Pancreatic_NET
Temozolomide & low-dose RT,LDRT,"Adjuvant therapy, elderly or poor performance status patients",Glioblastoma
Temozolomide & low-dose RT,Temozolomide & low-dose RT,"Adjuvant therapy, elderly or poor performance status patients",Glioblastoma
Temozolomide monotherapy,Temozolomide monotherapy,"First-line induction therapy, older or ""unfit"" patients","CNS_lymphoma,Acute_myeloid_leukemia,Myelodysplastic_syndrome,Pancreatic_NET,Glioblastoma,Soft_tissue_sarcoma,Anaplastic_glioma,Neuroendocrine_tumors,Small_cell_lung_cancer,Low-grade_glioma,Melanoma"
"Temozolomide, then Temozolomide & RT, then Temozolomide","Temozolomide, then Temozolomide & RT, then Temozolomide",Adjuvant therapy,Anaplastic_glioma
Temsirolimus & Rituximab,Temsirolimus & Rituximab,"Relapsed or refractory, non-randomized or retrospective data",Mantle_cell_lymphoma
Temsirolimus monotherapy,Temsirolimus monotherapy,"Relapsed or refractory, subsequent lines of therapy","CNS_lymphoma,Follicular_lymphoma,Diffuse_large_B-cell_lymphoma,Renal_cell_carcinoma,Mantle_cell_lymphoma,Endometrial_cancer"
Teniposide monotherapy,Teniposide monotherapy,"Extensive stage, induction",Small_cell_lung_cancer
Thal-Dex,Thal-Dex,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
Thal-Dex,Thal/Dex,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
Thal-Dex,ThalDex,"First-line therapy (including transplant ineligible), randomized data","Multiple_myeloma_relapsedrefractory,Multiple_myeloma_induction"
Thalidomide & Rituximab,Thalidomide & Rituximab,"First-line therapy, non-randomized or retrospective data",Waldenstrom_macroglobulinemia
Thalidomide monotherapy,Thalidomide monotherapy,"Relapsed or refractory, non-randomized or retrospective data","Multiple_myeloma_relapsedrefractory,Polycythemia_vera"
Thioguanine monotherapy,Thioguanine monotherapy,"First-line therapy, non-randomized or retrospective data",Waldenstrom_macroglobulinemia
Thiotepa monotherapy,Thiotepa monotherapy,Intravesical chemotherapy,Bladder_cancer
Tinzaparin monotherapy,Tinzaparin monotherapy,"VTE treatment, all lines of therapy",Venous_thromboembolism_(VTE)
Tisagenlecleucel monotherapy,Tisagenlecleucel monotherapy,"Relapsed or refractory, further lines of therapy","Diffuse_large_B-cell_lymphoma,Transformed_lymphoma"
Tocilizumab monotherapy,Tocilizumab monotherapy,"HHV-8-negative/""Idiopathic"" multicentric Castleman disease, all lines of therapy",Castleman_disease
Topotecan & Bevacizumab,Topotecan & Bevacizumab,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Topotecan monotherapy,Topotecan monotherapy,"Persistent, recurrent, or metastatic disease, first-line therapy","CNS_lymphoma,Ovarian_cancer,Cervical_cancer,Small_cell_lung_cancer,Endometrial_cancer"
Trabectedin monotherapy,Trabectedin monotherapy,"Relapsed or recurrent disease, platinum-resistant","Ovarian_cancer,Soft_tissue_sarcoma"
Trametinib monotherapy,Trametinib monotherapy,"Advanced or metastatic disease, BRAF inhibitor-naive",Melanoma_BRAF-mutated
Trastuzumab monotherapy,Trastuzumab monotherapy,Maintenance for metastatic or unresectable disease,Breast_cancer_HER2-positive
Treosulfan monotherapy,Treosulfan monotherapy,"Relapsed or recurrent disease, platinum-resistant",Ovarian_cancer
Trifluridine and tipiracil monotherapy,Trifluridine and tipiracil monotherapy,"Advanced or metastatic disease, subsequent lines of therapy","Gastric_cancer,Colon_cancer"
UFT monotherapy,UFT monotherapy,Adjuvant chemotherapy,Rectal_cancer
UFTM,UFTM,"Metastatic or locally advanced disease, first-line",Gastric_cancer
VA,VA,All lines of therapy,Rhabdomyosarcoma
VAC,VAC,All lines of therapy,Rhabdomyosarcoma
VACA,VACA,Neoadjuvant therapy,Ewings_sarcoma
VAD+C,VAD & C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VAD / C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VAD/C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VAD and C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VAD+C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VAD&C,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAD+C,VADC,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VAI,VAI,Adjuvant therapy,"Rhabdomyosarcoma,Ewings_sarcoma"
VAI,IVA,Adjuvant therapy,"Rhabdomyosarcoma,Ewings_sarcoma"
VAIA,VAIA,Neoadjuvant therapy,Ewings_sarcoma
VAMP,VAMP,"Untreated, early-stage favorable (ESF)",Hodgkin_lymphoma
VAdCA,VAdCA,Relapsed or refractory or metastatic,Ewings_sarcoma
VBM,VBM,Neoadjuvant chemotherapy,Penile_cancer
VDC,VDC,First-line therapy (including transplant ineligible),"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
VDC,CyBorD,First-line therapy (including transplant ineligible),"Multiple_myeloma_relapsedrefractory,Light-chain_(AL)_amyloidosis"
VEBEP,VEBEP,"Untreated, advanced stage",Hodgkin_lymphoma
VEPEMB,VEPEMB,"Untreated, elderly",Hodgkin_lymphoma
VH,VH,Neoadjuvant chemotherapy,Breast_cancer_HER2-positive
VIDE,VIDE,Neoadjuvant therapy,Ewings_sarcoma
VIE,VIE,All lines of therapy,Rhabdomyosarcoma
VIP,VIP,Upfront therapy for disseminated disease,"Testicular_cancer,Thymoma"
VIPD,VIPD,Consolidation after upfront therapy,Extranodal_NKT-cell_lymphoma_nasal_type
VMD,VMD,First-line therapy (including transplant ineligible),Light-chain_(AL)_amyloidosis
VMPT,VMPT,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
VP,VP,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
VR,VR,"Advanced disease, first-line therapy, non-randomized or retrospective data","Waldenstrom_macroglobulinemia,Mantle_cell_lymphoma,Follicular_lymphoma"
VR-CAP,VR-CAP,"First-line therapy, randomized data",Mantle_cell_lymphoma
VR-CAP,VRCAP,"First-line therapy, randomized data",Mantle_cell_lymphoma
VR-CAP,VR/CAP,"First-line therapy, randomized data",Mantle_cell_lymphoma
VR-CHOP,VR/CHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
VR-CHOP,VRCHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
VR-CHOP,VR-CHOP,"Advanced disease, first-line therapy, non-randomized or retrospective data","Mantle_cell_lymphoma,Follicular_lymphoma"
VR-CP,VRCP,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
VR-CP,VR-CP,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
VR-CP,VR/CP,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
VTD,VTD,"Relapsed or refractory, randomized data",Multiple_myeloma_relapsedrefractory
VTD-PACE,VTDPACE,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
VTD-PACE,VTD/PACE,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
VTD-PACE,VTD-PACE,"First-line therapy (including transplant ineligible), randomized data",Multiple_myeloma_induction
Vandetanib monotherapy,Vandetanib monotherapy,"Differentiated thyroid cancer, all lines of therapy",Thyroid_cancer
VcR-CVAD,VcR-CVAD,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VcR-CVAD,VcR/CVAD,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VcR-CVAD,VcRCVAD,"First-line therapy, non-randomized or retrospective data",Mantle_cell_lymphoma
VeIP,VeIP,"Relapsed or refractory, salvage therapy",Testicular_cancer
Vemurafenib monotherapy,Vemurafenib monotherapy,All lines of therapy,"Melanoma_BRAF-mutated,Langerhans_cell_histiocytosis,Multiple_myeloma_relapsedrefractory,Thyroid_cancer_BRAF-mutated,Erdheim-Chester_disease,BRAF,Hairy_cell_leukemia"
Venetoclax & Rituximab,Venetoclax & Rituximab,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN and R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN+R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VENR,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN & R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN&R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN / R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax & Rituximab,VEN/R,"Relapsed or refractory, randomized data",Chronic_lymphocytic_leukemia_(CLLSLL)
Venetoclax monotherapy,Venetoclax monotherapy,"Relapsed or refractory, non-randomized or retrospective data",Chronic_lymphocytic_leukemia_(CLLSLL)
Vinblastine monotherapy,Vinblastine monotherapy,"Relapsed or refractory, all lines of therapy",Hodgkin_lymphoma
Vincristine & Prednisone,Vincristine & Prednisone,Blast crisis,"Diffuse_large_B-cell_lymphoma,Chronic_myelogenous_leukemia"
Vincristine monotherapy,Vincristine monotherapy,Relapsed or refractory,"Thrombotic_thrombocytopenic_purpura,Wilms_tumor"
Vinflunine monotherapy,Vinflunine monotherapy,"Locally advanced or metastatic disease, subsequent lines",Bladder_cancer
Vinorelbine monotherapy,Vinorelbine monotherapy,"Persistent, recurrent, or metastatic disease, first-line therapy","Non-small_cell_lung_cancer,Diffuse_large_B-cell_lymphoma,Ovarian_cancer,Cervical_cancer,Mesothelioma,Hodgkin_lymphoma,Small_cell_lung_cancer"
Vismodegib monotherapy,Vismodegib monotherapy,"Advanced or metastatic disease, all lines of therapy","Cutaneous_basal_cell_carcinoma,SMO_or_PTCH-1_(Hedgehog)"
Vorinostat & Rituximab,Vorinostat & Rituximab,"Relapsed or refractory, non-randomized or retrospective data",Follicular_lymphoma
Vorinostat monotherapy,Vorinostat monotherapy,Relapsed or refractory,"Cutaneous_T-cell_lymphoma,Marginal_zone_lymphoma,Follicular_lymphoma"
Warfarin monotherapy,Warfarin monotherapy,All lines of therapy,"Antiphospholipid_antibody_syndrome,Venous_thromboembolism_(VTE)"
ZRd,ZRd,"Relapsed or refractory, non-randomized or retrospective data",Multiple_myeloma_relapsedrefractory
ddAC,ddAC,Neoadjuvant chemotherapy,"Breast_cancer,Breast_cancer_triple_negative"
dmCODOX-M - Modified Magrath,dmCODOXM,Upfront therapy,HIV-associated_lymphoma
dmCODOX-M - Modified Magrath,dmCODOX-M - Modified Magrath,Upfront therapy,HIV-associated_lymphoma
dmCODOX-M - Modified Magrath,dmCODOX-M,Upfront therapy,HIV-associated_lymphoma
dmCODOX-M - Modified Magrath,dmCODOX/M,Upfront therapy,HIV-associated_lymphoma
dmCODOX-M/IVAC - Modified Magrath,dmCODOX-M/IVAC - Modified Magrath,Upfront therapy,HIV-associated_lymphoma
dmCODOX-M/IVAC - Modified Magrath,dmCODOX-M/IVAC,Upfront therapy,HIV-associated_lymphoma
eBEACOPP,eBEACOPP,"Untreated, early-stage unfavorable (ESU)",Hodgkin_lymphoma
m-BACOD,m/BACOD,Upfront therapy,HIV-associated_lymphoma
m-BACOD,m-BACOD,Upfront therapy,HIV-associated_lymphoma
m-BACOD,mBACOD,Upfront therapy,HIV-associated_lymphoma
mDCF,mDCF,"Metastatic disease, first-line therapy","Esophageal_cancer,Anal_cancer"
mDCF & Bevacizumab,mDCF  and  Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF+Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF/Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF and Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF / Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF + Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mDCF & Bevacizumab,mDCF & Bevacizumab,Metastatic or locally advanced disease (non-radiation/surgery candidate),Esophageal_cancer
mFOLFIRINOX,mFOLFIRINOX,Adjuvant therapy,Pancreatic_cancer
"mFOLFIRINOX, Gemcitabine, RT","mFOLFIRINOX, Gemcitabine, RT","Induction therapy for locally advanced disease, potentially resectable",Pancreatic_cancer
mFOLFOX6,mFOLFOX6,Adjuvant therapy,Colon_cancer
mFOLFOX6 & Bevacizumab,FOLFOX/B,"Advanced or metastatic disease, first-line",Colon_cancer
mFOLFOX6 & Bevacizumab,FOLFOXB,"Advanced or metastatic disease, first-line",Colon_cancer
mFOLFOX6 & Bevacizumab,FOLFOX-B,"Advanced or metastatic disease, first-line",Colon_cancer
mFOLFOX6 & Bevacizumab,mFOLFOX6 & Bevacizumab,"Advanced or metastatic disease, first-line",Colon_cancer
mFOLFOX6 & Cetuximab,mFOLFOX6 / Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6+Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6/Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6  and  Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6 & Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6 + Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & Cetuximab,mFOLFOX6 and Cetuximab,Adjuvant therapy,"Esophageal_cancer,Colon_cancer_KRAS_wild-type"
mFOLFOX6 & RT,mFOLFOX6/RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6 & RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6 and RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6  and  RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6 / RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6 + RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOX6 & RT,mFOLFOX6+RT,Neoadjuvant therapy,Rectal_cancer
mFOLFOXIRI & Cetuximab,mFOLFOXIRI & Cetuximab,"Advanced or metastatic disease, first-line",Colon_cancer_KRAS_wild-type
mLSG15,mLSG15,Untreated,Adult_T-cell_leukemia-lymphoma
nab-Paclitaxel & Atezolizumab,nab-Paclitaxel & Atezolizumab,"Metastatic disease, first-line therapy",Breast_cancer_triple_negative
nab-Paclitaxel monotherapy,nab-Paclitaxel monotherapy,"Metastatic disease, first-line therapy",Breast_cancer_triple_negative
